glycine has been researched along with Neoplasms in 233 studies
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The hyperhomocysteinemia, suppressed immunity, and altered oxidative metabolism observed in atherosclerosis and dementia are attributed to deficiency of adenosyl methionine which results from increased polyamine biosynthesis by pathogenic microbes that are demonstrated in atherosclerotic plaques and cerebral plaques." | 9.05 | Environmental Pollution, Oxidative Stress and Thioretinaco Ozonide: Effects of Glyphosate, Fluoride and Electromagnetic Fields on Mitochondrial Dysfunction in Carcinogenesis, Atherogenesis and Aging. ( McCully, KS, 2020) |
| "Glycine protects skeletal muscle from cancer-induced wasting and loss of function, reduces the oxidative and inflammatory burden, and reduces the expression of genes associated with muscle protein breakdown in cancer cachexia." | 7.80 | Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia. ( Chee, A; Ham, DJ; Koopman, R; Lynch, GS; Murphy, KT, 2014) |
| "In patients with solid tumors, ixazomib was associated with a manageable safety profile, limited antitumor activity, and evidence of downstream proteasome inhibition effects." | 6.80 | Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. ( Berg, D; Berger, AJ; Di Bacco, A; Gao, F; Gupta, N; Hui, AM; Infante, JR; Kalebic, T; Kauh, JS; Lin, J; Liu, G; Siu, LL; Smith, DC; Sullivan, D; Thompson, JA; Tirrell, S; Vlahovic, G, 2015) |
| "Glyphosate has been detected in urine, blood and maternal milk and has been found to induce the generation of reactive oxygen species (ROS) and several cytotoxic and genotoxic effects in vitro and in animal models directly or indirectly through its metabolite, aminomethylphosphonic acid (AMPA)." | 6.72 | Pleiotropic Outcomes of Glyphosate Exposure: From Organ Damage to Effects on Inflammation, Cancer, Reproduction and Development. ( Marino, M; Meccariello, R; Mele, E; Nori, SL; Santoro, A; Viggiano, A, 2021) |
| " The hyperhomocysteinemia, suppressed immunity, and altered oxidative metabolism observed in atherosclerosis and dementia are attributed to deficiency of adenosyl methionine which results from increased polyamine biosynthesis by pathogenic microbes that are demonstrated in atherosclerotic plaques and cerebral plaques." | 5.05 | Environmental Pollution, Oxidative Stress and Thioretinaco Ozonide: Effects of Glyphosate, Fluoride and Electromagnetic Fields on Mitochondrial Dysfunction in Carcinogenesis, Atherogenesis and Aging. ( McCully, KS, 2020) |
| "This systematic review and meta-analysis rigorously examines the relationship between glyphosate exposure and risk of lymphohematopoietic cancer (LHC) including NHL, Hodgkin lymphoma (HL), multiple myeloma (MM), and leukemia." | 4.93 | Systematic review and meta-analysis of glyphosate exposure and risk of lymphohematopoietic cancers. ( Chang, ET; Delzell, E, 2016) |
| "Glycine protects skeletal muscle from cancer-induced wasting and loss of function, reduces the oxidative and inflammatory burden, and reduces the expression of genes associated with muscle protein breakdown in cancer cachexia." | 3.80 | Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia. ( Chee, A; Ham, DJ; Koopman, R; Lynch, GS; Murphy, KT, 2014) |
| "The proteasome was validated as an oncology target following the clinical success of VELCADE (bortezomib) for injection for the treatment of multiple myeloma and recurring mantle cell lymphoma." | 3.76 | Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. ( Bannerman, B; Berger, A; Blank, J; Bolen, J; Bruzzese, F; Cao, Y; Dick, L; Fitzgerald, M; Fleming, P; Garcia, K; Hales, P; Kupperman, E; Lee, EC; Liu, J; Manfredi, M; Rolfe, M; Tsu, C; Yang, Y; Yu, J; Yu, L, 2010) |
| "Anemia is a common side effect of myelosuppressive chemotherapy; however, chemotherapy-induced anemia (CIA) management options are suboptimal." | 3.30 | Open-label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non-myeloid malignancies. ( Gabrail, NY; Glaspy, J; Henry, DH; Lee, T; Locantore-Ford, P; Modelska, K; Samal, V, 2023) |
| " We explored the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of ivosidenib in these populations." | 2.94 | Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. ( Agresta, S; Dai, D; Fan, B; Gliser, C; Goyal, L; Jiang, L; Liu, G; Lowery, MA; Manyak, E; Mellinghoff, IK; Nimkar, T; Pandya, SS; Prahl Judge, M; Tap, WD; Wen, PY; Yang, H, 2020) |
| " The clinical drug-drug interaction study results were reconciled well by a physiologically based pharmacokinetic model that incorporated a minor contribution of CYP3A to overall ixazomib clearance and quantitatively considered the strength of induction of CYP3A and intestinal P-glycoprotein by rifampin." | 2.87 | Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Ana ( Bessudo, A; Esseltine, DL; Gupta, N; Hanley, MJ; Ke, A; Liu, G; Nemunaitis, J; O'Neil, BH; Patel, C; Rasco, DW; Rowland Yeo, K; Sharma, S; Venkatakrishnan, K; Wang, B; Xia, C; Zhang, X, 2018) |
| "Conventional therapies for malignant tumors have limitations and disadvantages." | 2.82 | Current status of cancer starvation therapy. ( Li, J; Lin, J; Tong, D, 2022) |
| "We examine the implications of αVβ6 in cancer progression and the promotion of epithelial-mesenchymal transition (EMT) by contributing to the activation of transforming growth factor beta TGF-β." | 2.82 | Integrin Alpha v Beta 6 (αvβ6) and Its Implications in Cancer Treatment. ( Brzozowska, E; Deshmukh, S, 2022) |
| "Eligible adults with advanced malignancies for which no further effective therapy was available received a single dose of ixazomib on day 1 of the pharmacokinetic cycle; patients with normal hepatic function, moderate hepatic impairment or severe hepatic impairment received 4 mg, 2." | 2.82 | Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment. ( Falchook, G; Fu, S; Gupta, N; Hanley, MJ; Labotka, R; Nemunaitis, J; Norris, RE; Perez, R; Qian, MG; Venkatakrishnan, K; Yang, H, 2016) |
| "In patients with solid tumors, ixazomib was associated with a manageable safety profile, limited antitumor activity, and evidence of downstream proteasome inhibition effects." | 2.80 | Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. ( Berg, D; Berger, AJ; Di Bacco, A; Gao, F; Gupta, N; Hui, AM; Infante, JR; Kalebic, T; Kauh, JS; Lin, J; Liu, G; Siu, LL; Smith, DC; Sullivan, D; Thompson, JA; Tirrell, S; Vlahovic, G, 2015) |
| "Archival tumors were assessed for potential molecular biomarkers with multiplex mutation testing." | 2.79 | Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. ( Aisner, DL; Anderson, RT; Astling, DP; Bowles, DW; Diamond, JR; Eckhardt, SG; Freas, E; Gore, L; Jimeno, A; Keysar, SB; Lam, ET; Leong, S; Maniar, M; Messersmith, WA; Ren, C; Tan, AC; Varella-Garcia, M; Vogler, BW; Weekes, CD; Wilhelm, F, 2014) |
| "Gemcitabine was administered on days 1, 8, and 15 on a 28-day cycle and rigosertib on days 1, 4, 8, 11, 15, and 18." | 2.77 | Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. ( Adjei, AA; Dy, GK; Eckhardt, SG; Jimeno, A; Ma, WW; Maniar, M; Messersmith, WA; Ren, C; Weekes, CD; Whitworth, A; Wilhelm, F, 2012) |
| "This Phase Ib dose-escalating study investigated safety, maximum tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK) and clinical antitumour activity of tosedostat (CHR-2797), an orally bioavailable aminopeptidase inhibitor, in combination with paclitaxel." | 2.75 | A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours. ( Bone, EA; de Jonge, M; Desar, I; Eskens, FA; Hooftman, L; Timmer-Bonte, JN; van Herpen, CM; Verweij, J, 2010) |
| " The terminal half-life for CHR-2797 is approximately 1 to 3." | 2.74 | A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors. ( Attard, G; Bone, EA; Carter, J; De Bono, JS; Harris, A; Hayward, N; Hooftman, L; Protheroe, A; Reid, AH; Shaw, HM; Spicer, J; Vidal, L, 2009) |
| "Patients had solid tumors refractory to standard therapy." | 2.73 | Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. ( Baker, SD; Donehower, RC; Hidalgo, M; Jimeno, A; Laheru, D; Li, J; Maniar, M; Messersmith, WA; Rudek, MA, 2008) |
| "Glyphosate has been detected in urine, blood and maternal milk and has been found to induce the generation of reactive oxygen species (ROS) and several cytotoxic and genotoxic effects in vitro and in animal models directly or indirectly through its metabolite, aminomethylphosphonic acid (AMPA)." | 2.72 | Pleiotropic Outcomes of Glyphosate Exposure: From Organ Damage to Effects on Inflammation, Cancer, Reproduction and Development. ( Marino, M; Meccariello, R; Mele, E; Nori, SL; Santoro, A; Viggiano, A, 2021) |
| "Here, we review its role in cancer by focusing on key enzymes with tumor-promoting functions and important products of the SGOCP that are of physiological relevance for tumorigenesis." | 2.66 | The complexity of the serine glycine one-carbon pathway in cancer. ( Diaz-Meco, MT; Moscat, J; Reina-Campos, M, 2020) |
| " The test statistics for these permutation tests are functions of p values from a standard test for dose-response trend applied to each specific type of tumor." | 2.66 | Accounting for Multiple Comparisons in Statistical Analysis of the Extensive Bioassay Data on Glyphosate. ( Crouch, E; Crump, C; Crump, K; Haseman, J; Zelterman, D, 2020) |
| "Serine encounters diverse fates in cancer cells, including being charged onto tRNAs for protein synthesis, providing head groups for sphingolipid and phospholipid synthesis, and serving as a precursor for cellular glycine and one-carbon units, which are necessary for nucleotide synthesis and methionine cycle reloading." | 2.66 | Reprogramming of serine, glycine and one-carbon metabolism in cancer. ( Li, AM; Ye, J, 2020) |
| "Metabolic reprogramming in cancer cells entails activities that involve several enzymes and metabolites to convert nutrient into building blocks that alter energy metabolism to fuel rapid cell division." | 2.66 | Cancer Cell Metabolites: Updates on Current Tracing Methods. ( Maniam, S, 2020) |
| "The objective of this review is to evaluate the mechanism of activity, efficacy and dosing of rigosertib." | 2.49 | Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer. ( Fan, AC; Felsher, DW; O'Rourke, JJ; Praharaj, DR, 2013) |
| " Presenting adverse effects of glyphosate and its formulations we focused on the role of glyphosate formulations in hormonal disorders by impeding the expression of steroidogenic acute regulatory protein and the inhibition of aromatase activity." | 2.49 | [Glyphosate and its formulations--toxicity, occupational and environmental exposure]. ( Bukowska, B; Kwiatkowska, M; Paweł, J, 2013) |
| "To examine potential cancer risks in humans, we reviewed the epidemiologic literature to evaluate whether exposure to glyphosate is associated causally with cancer risk in humans." | 2.48 | Epidemiologic studies of glyphosate and cancer: a review. ( Lundin, JI; Mandel, JS; Mink, PJ; Sceurman, BK, 2012) |
| "About 80% of human tumors, of various origins, express high levels of PLK transcripts." | 2.45 | Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. ( Schöffski, P, 2009) |
| "The anticancer activity of produced carbon nanomaterial revealed that it inhibited the BTK protein and its downstream pathways, including PLC and Akt proteins, at the cellular level." | 1.91 | Identification and Biological Evaluation of a Water-Soluble Fullerene Nanomaterial as BTK Kinase Inhibitor. ( Balin, K; Calvaresi, M; Korzuch, J; Malarz, K; Marforio, TD; Mrozek-Wilczkiewicz, A; Musiol, R; Serda, M, 2023) |
| "While many cancer cells cultured in a standard tissue culture medium depend on exogenous serine for optimal growth, here we report that these cells are less sensitive to serine/glycine depletion in medium containing physiological levels of metabolites." | 1.62 | The impact of physiological metabolite levels on serine uptake, synthesis and utilization in cancer cells. ( Cheung, EC; Driscoll, PC; Hennequart, M; Labuschagne, CF; Legrave, NM; Pilley, SE; Tajan, M; Vousden, KH, 2021) |
| "Cancer is driven by somatic mutations that result in a cellular fitness advantage." | 1.62 | Low immunogenicity of common cancer hot spot mutations resulting in false immunogenic selection signals. ( Claeys, A; Luijts, T; Marchal, K; Van den Eynden, J, 2021) |
| "I then present two exposure-cancer cases, namely talcum powder-ovarian cancer and glyphosate-non-Hodgkin lymphoma, that led to civil lawsuits decided, in the United States, in favor of the claimants." | 1.56 | Difficulties in establishing a causal link between chemical exposures and cancer cannot be overcome by court assessments. ( Dragani, TA, 2020) |
| "Thus, rigosertib kills cancer cells by destabilizing microtubules, in agreement with our original findings." | 1.56 | Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent. ( Akhmanova, A; Chen, Y; Cho, MY; Gilbert, LA; Horlbeck, MA; Jost, M; Kampmann, M; Krenning, L; Menchon, G; Prota, AE; Rai, A; Steinmetz, MO; Stern, JJ; Tanenbaum, ME; Weissman, JS, 2020) |
| "A major hallmark of cancer is a perturbed metabolism resulting in high demand for various metabolites, glucose being the most well studied." | 1.51 | Analysis of glucose-derived amino acids involved in one-carbon and cancer metabolism by stable-isotope tracing gas chromatography mass spectrometry. ( Gu, W; Herring, J; Ou, Y; Sowers, ML; Tang, H; Zhang, K; Zhang, W, 2019) |
| "The mechanisms underlying cancer cachexia - the proximate cause of at least 20% of cancer-related deaths - have until recently remained rather obscure." | 1.51 | Nutraceutical targeting of TLR4 signaling has potential for prevention of cancer cachexia. ( Iloki-Assanga, S; Lujany, LML; McCarty, MF, 2019) |
| "Scientists worldwide endorse IARC cancer evaluations and process." | 1.48 | Commentary: IARC Monographs Program and public health under siege by corporate interests. ( Huff, J; Infante, PF; Melnick, R; Vainio, H, 2018) |
| "Rational and effective cancer prevention activities depend on scientifically sound and unbiased assessments of the carcinogenic potential of suspected agents." | 1.48 | On the International Agency for Research on Cancer classification of glyphosate as a probable human carcinogen. ( Tarone, RE, 2018) |
| "It is a promising target for cancer drug development." | 1.46 | Several inhibitors of the Plk1 Polo-Box Domain turn out to be non-specific protein alkylators. ( Archambault, V; Normandin, K, 2017) |
| " We have identified a novel (E)-styrylsulfonyl methylpyridine [(E)-N-(2-methoxy-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)pyridin-3-yl)methanesulfonamide (TL-77)] which has shown improved oral bioavailability compared with ON01910." | 1.42 | In vitro antitumor mechanism of (E)-N-(2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyridin-3-yl)methanesulfonamide. ( Bradshaw, TD; Laughton, CA; Lu, T; Wang, S, 2015) |
| "There were no associations with other cancers." | 1.42 | Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis. ( Aasly, J; Agalliu, I; Bressman, S; Friedman, E; Giladi, N; Hassin-Baer, S; Inzelberg, R; Marti-Masso, JF; Mirelman, A; Orr-Urtreger, A; Ruiz-Martinez, J; San Luciano, M; Saunders-Pullman, R; Waro, B, 2015) |
| "The cytotoxicity to cancer cell lines of the fullerene-glycine derivatives was evaluated by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) and flow cytometry." | 1.42 | Synthesis and properties of novel water-soluble fullerene-glycine derivatives as new materials for cancer therapy. ( Duan, J; Jiang, G; Li, G; Yin, F, 2015) |
| "Previous work has shown that some cancer cells are highly dependent on serine/glycine uptake for proliferation." | 1.40 | Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells. ( Labuschagne, CF; Mackay, GM; Maddocks, OD; van den Broek, NJ; Vousden, KH, 2014) |
| "However, cancer NIR fluorescent sensors are very challenging to develop because they are required to exhibit good specificity and low toxicity as an eligible contrast agent." | 1.40 | Synthesis and characterization of a glycine-modified heptamethine indocyanine dye for in vivo cancer-targeted near-infrared imaging. ( Liu, T; Luo, S; Qi, Q; Shi, C; Tan, X; Wang, Y, 2014) |
| "Recent observations on cancer cell metabolism indicate increased serine synthesis from glucose as a marker of poor prognosis." | 1.39 | Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. ( Bertino, JR; Boros, LG; Chan, LL; DiPaola, RS; Dolfi, SC; Dvorzhinski, D; Gounder, M; Hirshfield, KM; Lin, H; Markert, EK; Oltvai, ZN; Qiu, J; Tedeschi, PM; Vazquez, A, 2013) |
| "Glycine is a nonessential amino acid that is reversibly converted from serine intracellularly by serine hydroxymethyltransferase." | 1.39 | Glyphosate and AMPA inhibit cancer cell growth through inhibiting intracellular glycine synthesis. ( Ge, D; Lambrechts, MJ; Li, Q; Liu, S; Xi, M; Yin, R; You, Z; Zhang, Q, 2013) |
| "We propose that patients whose tumors show this phenotype will be sensitive to folate antagonists targeting thymidylate or purine biosynthesis." | 1.39 | Overexpression of the mitochondrial folate and glycine-serine pathway: a new determinant of methotrexate selectivity in tumors. ( Bertino, JR; Tedeschi, PM; Vazquez, A, 2013) |
| "TICs from primary NSCLC tumors express high levels of the oncogenic stem cell factor LIN28B and GLDC, which are both required for TIC growth and tumorigenesis." | 1.38 | Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. ( Ahmed, DA; Ang, HS; Bhakoo, KK; Jayapal, SR; Kaldis, P; Lim, B; Lim, EH; Ma, S; Mitchell, W; Nga, ME; Nichane, M; Noghabi, MS; Pang, YH; Rai, A; Robson, P; Shyh-Chang, N; Sing, WP; Soh, BS; Soo, RA; Sun, LL; Swarup, S; Tai, BC; Tam, J; Tan, C; Thirugananam, A; Umashankar, S; Yang, H; Yu, Q; Zhang, WC, 2012) |
| "The in vivo anticancer activity study with HT-29 colon cancer cell xenografted mice showed that the intratumorally injected PCC hydrogel inhibited the tumor growth more effectively relative to CPT alone (-29% vs." | 1.38 | Injectable poly(organophosphazene)-camptothecin conjugate hydrogels: synthesis, characterization, and antitumor activities. ( Cho, JK; Chun, C; Kuh, HJ; Song, SC, 2012) |
| "Camptothecins have been characterized as inhibitors of DNA topoisomerase I (TOP1), although a correlation between TOP1 expression and activity is not well established in clinical biopsies." | 1.36 | Inhibition of epidermal growth factor receptor-overexpressing cancer cells by camptothecin, 20-(N,N-diethyl) glycinate. ( Efferth, T; Konkimalla, VB, 2010) |
| "At 30 and 50 mg/kg, the urinary bladder tumors were accompanied by evidence of increased urine solids." | 1.34 | Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar. ( Arnold, LL; Cohen, SM; Dominick, MA; Minnema, D; Sanderson, TP; Schilling, BE; Tannehill-Gregg, SH; Ulland, B; Voelker, R; Waites, CR, 2007) |
| "Glyphosate is a broad-spectrum herbicide that is one of the most frequently applied pesticides in the world." | 1.33 | Cancer incidence among glyphosate-exposed pesticide applicators in the Agricultural Health Study. ( Alavanja, MC; Blair, A; De Roos, AJ; Dosemeci, M; Hoppin, JA; Rusiecki, JA; Sandler, DP; Svec, M, 2005) |
| "Recently, four cancer-associated mutants of the A-alpha subunit have been described: Glu64-->Asp in lung carcinoma, Glu64-->Gly in breast carcinoma, Arg418-->Trp in melanoma, and Delta171 - 589 in breast carcinoma." | 1.31 | Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene. ( Pham, HT; Ruediger, R; Walter, G, 2001) |
| "Hypocitrullinemia in lung cancer patients was marked, and possible mechanisms to account for this are discussed." | 1.27 | Serum amino acids in weight-losing patients with cancer and tuberculosis. ( De Guel, FJ; Duncan, EJ; Gevers, W; Jardine, L; Levin, L, 1983) |
| "[15N]Glycine was used as the tracer with a prime to infusion ratio of 1300 to 3300 min and a continuous-infusion rate of 0." | 1.27 | Tracer priming in human protein turnover studies with [15N]glycine. ( Brennan, MF; Daly, J; Horowitz, GD; Jeevanandam, M; Lowry, SF; Mihranian, MH; Rose, D, 1985) |
| "This study suggests that some malignant tumors can increase whole body protein synthesis and turnover in both the malnourished and fed state." | 1.26 | Whole body protein synthesis and turnover in normal man and malnourished patients with and without known cancer. ( Brennan, MF; Norton, JA; Stein, TP, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 86 (36.91) | 18.7374 |
| 1990's | 5 (2.15) | 18.2507 |
| 2000's | 23 (9.87) | 29.6817 |
| 2010's | 81 (34.76) | 24.3611 |
| 2020's | 38 (16.31) | 2.80 |
| Authors | Studies |
|---|---|
| Kato, S | 1 |
| Adashek, JJ | 1 |
| Subbiah, V | 2 |
| Fu, S | 3 |
| Sun, M | 1 |
| Nguyen, L | 1 |
| Brown, EJ | 1 |
| Yap, TA | 1 |
| Karp, DD | 1 |
| Piha-Paul, SA | 1 |
| Hong, DS | 1 |
| Alt, J | 1 |
| Gori, SS | 1 |
| Lemberg, KM | 1 |
| Pal, A | 1 |
| Veeravalli, V | 1 |
| Wu, Y | 1 |
| Aguilar, JMH | 1 |
| Dash, RP | 1 |
| Tenora, L | 1 |
| Majer, P | 1 |
| Sun, Q | 1 |
| Slusher, BS | 1 |
| Rais, R | 1 |
| Gan, Z | 1 |
| Zhang, M | 1 |
| Xie, D | 1 |
| Wu, X | 1 |
| Hong, C | 1 |
| Fu, J | 1 |
| Fan, L | 1 |
| Wang, S | 2 |
| Han, S | 1 |
| Hennequart, M | 2 |
| Labuschagne, CF | 2 |
| Tajan, M | 2 |
| Pilley, SE | 1 |
| Cheung, EC | 2 |
| Legrave, NM | 1 |
| Driscoll, PC | 1 |
| Vousden, KH | 3 |
| Abdollahi, P | 1 |
| Vandsemb, EN | 1 |
| Børset, M | 1 |
| Marino, M | 1 |
| Mele, E | 1 |
| Viggiano, A | 1 |
| Nori, SL | 1 |
| Meccariello, R | 1 |
| Santoro, A | 1 |
| Zarei, M | 1 |
| Hue, JJ | 1 |
| Hajihassani, O | 1 |
| Graor, HJ | 1 |
| Katayama, ES | 1 |
| Loftus, AW | 1 |
| Bajor, D | 1 |
| Rothermel, LD | 1 |
| Vaziri-Gohar, A | 1 |
| Winter, JM | 1 |
| Li, J | 4 |
| Tong, D | 1 |
| Lin, J | 3 |
| Song, Q | 1 |
| Yang, W | 1 |
| Deng, X | 1 |
| Zhang, Y | 4 |
| Xing, X | 1 |
| Chen, W | 1 |
| Liu, W | 1 |
| Hu, H | 1 |
| Brzozowska, E | 1 |
| Deshmukh, S | 1 |
| Sun, W | 1 |
| Zhao, E | 1 |
| Cui, H | 1 |
| Rushing, BR | 2 |
| Fogle, HM | 2 |
| Sharma, J | 2 |
| You, M | 2 |
| McCormac, JP | 2 |
| Molina, S | 2 |
| Sumner, S | 2 |
| Krupenko, NI | 2 |
| Krupenko, SA | 2 |
| Glaspy, J | 1 |
| Gabrail, NY | 1 |
| Locantore-Ford, P | 1 |
| Lee, T | 1 |
| Modelska, K | 1 |
| Samal, V | 1 |
| Henry, DH | 1 |
| Malarz, K | 1 |
| Korzuch, J | 1 |
| Marforio, TD | 1 |
| Balin, K | 1 |
| Calvaresi, M | 1 |
| Mrozek-Wilczkiewicz, A | 1 |
| Musiol, R | 1 |
| Serda, M | 1 |
| Qin, W | 1 |
| Chandra, J | 1 |
| Abourehab, MAS | 1 |
| Gupta, N | 8 |
| Chen, ZS | 1 |
| Kesharwani, P | 1 |
| Cao, HL | 1 |
| Kettle, JG | 1 |
| Bagal, SK | 1 |
| Barratt, D | 1 |
| Bodnarchuk, MS | 1 |
| Boyd, S | 1 |
| Braybrooke, E | 1 |
| Breed, J | 1 |
| Cassar, DJ | 1 |
| Cosulich, S | 1 |
| Davies, M | 1 |
| Davies, NL | 1 |
| Deng, C | 1 |
| Eatherton, A | 1 |
| Evans, L | 1 |
| Feron, LJ | 1 |
| Fillery, S | 1 |
| Gleave, ES | 1 |
| Goldberg, FW | 1 |
| Cortés González, MA | 1 |
| Guerot, C | 1 |
| Haider, A | 1 |
| Harlfinger, S | 1 |
| Howells, R | 1 |
| Jackson, A | 1 |
| Johnström, P | 1 |
| Kemmitt, PD | 1 |
| Koers, A | 1 |
| Kondrashov, M | 1 |
| Lamont, GM | 1 |
| Lamont, S | 1 |
| Lewis, HJ | 1 |
| Liu, L | 6 |
| Mylrea, M | 1 |
| Nash, S | 1 |
| Niedbala, MJ | 1 |
| Peter, A | 1 |
| Phillips, C | 1 |
| Pike, K | 1 |
| Raubo, P | 1 |
| Robb, GR | 1 |
| Ross, S | 1 |
| Sanders, MG | 1 |
| Schou, M | 1 |
| Simpson, I | 1 |
| Steward, O | 1 |
| Dalton, WB | 1 |
| Helmenstine, E | 1 |
| Walsh, N | 1 |
| Gondek, LP | 1 |
| Kelkar, DS | 1 |
| Read, A | 1 |
| Natrajan, R | 1 |
| Christenson, ES | 1 |
| Roman, B | 1 |
| Das, S | 2 |
| Zhao, L | 1 |
| Leone, RD | 1 |
| Shinn, D | 1 |
| Groginski, T | 1 |
| Madugundu, AK | 1 |
| Patil, A | 1 |
| Zabransky, DJ | 1 |
| Medford, A | 1 |
| Lee, J | 1 |
| Cole, AJ | 1 |
| Rosen, M | 1 |
| Thakar, M | 1 |
| Ambinder, A | 1 |
| Donaldson, J | 1 |
| DeZern, AE | 1 |
| Cravero, K | 1 |
| Chu, D | 1 |
| Madero-Marroquin, R | 1 |
| Pandey, A | 1 |
| Hurley, PJ | 1 |
| Lauring, J | 1 |
| Park, BH | 1 |
| McCarty, MF | 2 |
| Iloki-Assanga, S | 1 |
| Lujany, LML | 1 |
| Kellert, M | 1 |
| Lönnecke, P | 1 |
| Riedl, B | 1 |
| Koebberling, J | 1 |
| Hey-Hawkins, E | 1 |
| Reina-Campos, M | 1 |
| Diaz-Meco, MT | 1 |
| Moscat, J | 1 |
| Wang, Y | 4 |
| Janku, F | 1 |
| Piha-Paul, S | 1 |
| Hess, K | 1 |
| Broaddus, R | 1 |
| Shi, N | 1 |
| Overman, M | 1 |
| Kopetz, S | 1 |
| Naing, A | 1 |
| Hong, D | 1 |
| Tsimberidou, AM | 1 |
| Karp, D | 1 |
| Yao, J | 1 |
| Dragani, TA | 1 |
| Xiao, F | 2 |
| Shao, T | 1 |
| Jin, G | 1 |
| Crump, K | 1 |
| Crouch, E | 1 |
| Zelterman, D | 1 |
| Crump, C | 1 |
| Haseman, J | 1 |
| Berry, C | 1 |
| Li, AM | 1 |
| Ye, J | 1 |
| Kosciuk, T | 1 |
| Lin, H | 2 |
| Rusyn, I | 2 |
| Chiu, WA | 1 |
| Wright, FA | 1 |
| McCully, KS | 1 |
| Jost, M | 1 |
| Chen, Y | 1 |
| Gilbert, LA | 1 |
| Horlbeck, MA | 1 |
| Krenning, L | 1 |
| Menchon, G | 1 |
| Rai, A | 2 |
| Cho, MY | 1 |
| Stern, JJ | 1 |
| Prota, AE | 1 |
| Kampmann, M | 1 |
| Akhmanova, A | 1 |
| Steinmetz, MO | 1 |
| Tanenbaum, ME | 1 |
| Weissman, JS | 1 |
| Maniam, S | 2 |
| Yerlikaya, A | 1 |
| Kanbur, E | 1 |
| Stanley, BA | 1 |
| Tümer, E | 1 |
| Muthusamy, T | 1 |
| Cordes, T | 1 |
| Handzlik, MK | 1 |
| You, L | 1 |
| Lim, EW | 1 |
| Gengatharan, J | 1 |
| Pinto, AFM | 1 |
| Badur, MG | 1 |
| Kolar, MJ | 1 |
| Wallace, M | 1 |
| Saghatelian, A | 1 |
| Metallo, CM | 1 |
| Wei, J | 1 |
| Shi, Z | 1 |
| Na, R | 1 |
| Wang, CH | 1 |
| Resurreccion, WK | 1 |
| Zheng, SL | 1 |
| Hulick, PJ | 1 |
| Cooney, KA | 1 |
| Helfand, BT | 1 |
| Isaacs, WB | 1 |
| Xu, J | 3 |
| Zani, F | 1 |
| Hock, AK | 1 |
| Legrave, N | 1 |
| Maddocks, ODK | 1 |
| Ridgway, RA | 1 |
| Athineos, D | 1 |
| Suárez-Bonnet, A | 1 |
| Ludwig, RL | 1 |
| Novellasdemunt, L | 1 |
| Angelis, N | 1 |
| Li, VSW | 1 |
| Vlachogiannis, G | 1 |
| Valeri, N | 1 |
| Mainolfi, N | 1 |
| Suri, V | 1 |
| Friedman, A | 1 |
| Manfredi, M | 2 |
| Blyth, K | 1 |
| Sansom, OJ | 1 |
| Pan, S | 1 |
| Fan, M | 1 |
| Liu, Z | 2 |
| Li, X | 1 |
| Wang, H | 4 |
| Geeraerts, SL | 1 |
| Heylen, E | 1 |
| De Keersmaecker, K | 1 |
| Kampen, KR | 1 |
| Claeys, A | 1 |
| Luijts, T | 1 |
| Marchal, K | 1 |
| Van den Eynden, J | 1 |
| Zagefka, H | 1 |
| Huynh, HP | 1 |
| Senger, AR | 1 |
| Derington, CG | 1 |
| Colantonio, LD | 1 |
| Herrick, JS | 1 |
| Cook, J | 1 |
| King, JB | 1 |
| Rosenson, RS | 1 |
| Poudel, B | 1 |
| Monda, KL | 1 |
| Navar, AM | 1 |
| Mues, KE | 1 |
| Stevens, VW | 1 |
| Nelson, RE | 1 |
| Vanneman, ME | 1 |
| Muntner, P | 1 |
| Bress, AP | 1 |
| Ma, B | 1 |
| Ren, G | 1 |
| Yin, C | 1 |
| Shi, Y | 1 |
| Rahsepar, AA | 1 |
| Bluemke, DA | 1 |
| Habibi, M | 1 |
| Liu, K | 1 |
| Kawel-Boehm, N | 1 |
| Ambale-Venkatesh, B | 1 |
| Fernandes, VRS | 1 |
| Rosen, BD | 1 |
| Lima, JAC | 1 |
| Carr, JC | 1 |
| Freitag, TM | 1 |
| Chen-Sankey, JC | 1 |
| Duarte, DA | 1 |
| Ramsey, MW | 1 |
| Choi, K | 1 |
| Winkler-Heil, R | 1 |
| Hussain, M | 1 |
| Hofmann, W | 1 |
| Nicotera, AG | 1 |
| Dicanio, D | 1 |
| Pironti, E | 1 |
| Bonsignore, M | 1 |
| Cafeo, A | 1 |
| Efthymiou, S | 1 |
| Mondello, P | 1 |
| Salpietro, V | 1 |
| Houlden, H | 1 |
| Di Rosa, G | 1 |
| Hayes-Ryan, D | 1 |
| O'Donoghue, K | 1 |
| McCarthy, C | 1 |
| Totorika, A | 1 |
| Meaney, S | 1 |
| Pang, RD | 1 |
| Dormanesh, A | 1 |
| Hoang, Y | 1 |
| Chu, M | 1 |
| Allem, JP | 1 |
| Girón-Ortega, JA | 1 |
| Márquez-Coello, M | 1 |
| Gutiérrez-Saborido, D | 1 |
| Arizcorreta, A | 1 |
| Cuesta-Sancho, S | 1 |
| Girón-González, JA | 1 |
| Dovrat, G | 1 |
| Pevzner, S | 1 |
| Berthon, C | 1 |
| Lerner, A | 1 |
| Maimon, E | 1 |
| Vainer, R | 1 |
| Karpasas, M | 1 |
| Ben-Elyiahu, Y | 1 |
| Moisy, P | 1 |
| Bettelheim, A | 1 |
| Zilbermann, I | 1 |
| Vanden Broeck, SMP | 1 |
| Nelson, DJ | 1 |
| Collado, A | 1 |
| Falivene, L | 1 |
| Cavallo, L | 1 |
| Cordes, DB | 1 |
| Slawin, AMZ | 1 |
| Van Hecke, K | 1 |
| Nahra, F | 1 |
| Cazin, CSJ | 1 |
| Nolan, SP | 1 |
| Kranidiotis-Hisatomi, N | 1 |
| Yi, H | 1 |
| Oestreich, M | 1 |
| Kwiezinski, C | 1 |
| Weller, C | 1 |
| van Pinxteren, D | 1 |
| Brüggemann, M | 1 |
| Mertes, S | 1 |
| Stratmann, F | 1 |
| Herrmann, H | 1 |
| Treggiari, D | 1 |
| Tridello, G | 1 |
| Menin, L | 1 |
| Borruso, A | 1 |
| Pintani, E | 1 |
| Iansa, P | 1 |
| Cipolli, M | 1 |
| Melotti, P | 1 |
| Ren, L | 2 |
| Shu, X | 1 |
| Lin, W | 1 |
| Yang, P | 1 |
| Chen, J | 1 |
| Teo, KL | 1 |
| Yao, T | 1 |
| Zhao, X | 1 |
| Yang, X | 1 |
| Yu, DYW | 1 |
| Rogach, AL | 1 |
| Bordet, A | 1 |
| Leitner, W | 1 |
| Gao, S | 1 |
| Xia, F | 1 |
| Li, B | 2 |
| Abdul Razak, IB | 1 |
| Liu, Y | 3 |
| Lu, K | 1 |
| Brown, DE | 1 |
| Wang, R | 1 |
| Cheng, Y | 1 |
| Ni, S | 1 |
| Qu, H | 1 |
| Xing, H | 1 |
| Xu, Z | 1 |
| Zhu, X | 1 |
| Yuan, M | 1 |
| Wang, L | 1 |
| Yu, J | 2 |
| Li, Y | 2 |
| Yang, L | 1 |
| Liu, H | 1 |
| Cao, L | 1 |
| Zhang, S | 2 |
| Zhao, D | 1 |
| Yan, T | 1 |
| Yang, G | 1 |
| Lin, Z | 1 |
| Luo, M | 1 |
| Ye, N | 1 |
| Lee, SW | 1 |
| Carnicelli, J | 1 |
| Getya, D | 1 |
| Gitsov, I | 1 |
| Phillips, KS | 1 |
| Ren, D | 1 |
| Grützmacher, PG | 1 |
| Suarez, S | 1 |
| Tolosa, A | 1 |
| Gachot, C | 1 |
| Song, G | 1 |
| Wang, B | 4 |
| Presser, V | 1 |
| Mücklich, F | 1 |
| Anasori, B | 1 |
| Rosenkranz, A | 1 |
| Demireva, M | 1 |
| Armentrout, PB | 1 |
| Feng, D | 1 |
| Cao, K | 1 |
| He, ZZ | 1 |
| Knibbs, LD | 1 |
| Jalaludin, B | 1 |
| Leskinen, A | 1 |
| Roponen, M | 1 |
| Komppula, M | 1 |
| Jalava, P | 1 |
| Guo, PY | 1 |
| Xu, SL | 1 |
| Yang, BY | 1 |
| Hu, L | 1 |
| Zeng, XW | 1 |
| Chen, G | 1 |
| Yu, HY | 1 |
| Lin, L | 1 |
| Dong, G | 1 |
| Machulkin, AE | 1 |
| Shafikov, RR | 1 |
| Uspenskaya, AA | 1 |
| Petrov, SA | 1 |
| Ber, AP | 1 |
| Skvortsov, DA | 1 |
| Nimenko, EA | 1 |
| Zyk, NU | 1 |
| Smirnova, GB | 1 |
| Pokrovsky, VS | 1 |
| Abakumov, MA | 1 |
| Saltykova, IV | 1 |
| Akhmirov, RT | 1 |
| Garanina, AS | 1 |
| Polshakov, VI | 1 |
| Saveliev, OY | 1 |
| Ivanenkov, YA | 1 |
| Aladinskaya, AV | 1 |
| Finko, AV | 1 |
| Yamansarov, EU | 1 |
| Krasnovskaya, OO | 1 |
| Erofeev, AS | 1 |
| Gorelkin, PV | 1 |
| Dontsova, OA | 1 |
| Beloglazkina, EK | 1 |
| Zyk, NV | 1 |
| Khazanova, ES | 1 |
| Majouga, AG | 1 |
| Zheng, YK | 1 |
| Su, BJ | 1 |
| Wang, YQ | 1 |
| Wang, HS | 1 |
| Liao, HB | 1 |
| Liang, D | 1 |
| Shataer, D | 1 |
| Duan, XM | 1 |
| Xin, XL | 1 |
| Aisa, HA | 1 |
| Allu, SR | 1 |
| Ravotto, L | 1 |
| Troxler, T | 1 |
| Vinogradov, SA | 1 |
| Cheruku, RR | 1 |
| Tracy, EC | 1 |
| Tabaczynski, W | 1 |
| Missert, JR | 1 |
| Baumann, H | 1 |
| Pandey, RK | 1 |
| Rohde, JM | 1 |
| Karavadhi, S | 1 |
| Pragani, R | 1 |
| Fang, Y | 1 |
| Zhang, W | 3 |
| McIver, A | 1 |
| Zheng, H | 1 |
| Liu, Q | 1 |
| Davis, MI | 1 |
| Urban, DJ | 1 |
| Lee, TD | 1 |
| Cheff, DM | 1 |
| Hollingshead, M | 1 |
| Henderson, MJ | 1 |
| Martinez, NJ | 1 |
| Brimacombe, KR | 1 |
| Yasgar, A | 1 |
| Zhao, W | 1 |
| Klumpp-Thomas, C | 1 |
| Michael, S | 1 |
| Covey, J | 1 |
| Moore, WJ | 1 |
| Stott, GM | 1 |
| Li, Z | 3 |
| Simeonov, A | 1 |
| Jadhav, A | 1 |
| Frye, S | 1 |
| Hall, MD | 1 |
| Shen, M | 1 |
| Wang, X | 1 |
| Patnaik, S | 1 |
| Boxer, MB | 1 |
| Zhang, H | 3 |
| Cheng, C | 1 |
| Huang, B | 1 |
| Chen, R | 1 |
| Huang, Y | 1 |
| Chen, H | 1 |
| Pei, W | 1 |
| Katahara, S | 1 |
| Sugiyama, Y | 1 |
| Yamane, M | 1 |
| Komiya, Y | 1 |
| Sato, T | 1 |
| Chida, N | 1 |
| Antal, I | 1 |
| Koneracka, M | 1 |
| Kubovcikova, M | 1 |
| Zavisova, V | 1 |
| Jurikova, A | 1 |
| Khmara, I | 1 |
| Omastova, M | 1 |
| Micusik, M | 1 |
| Barathova, M | 1 |
| Jelenska, L | 1 |
| Kajanova, I | 1 |
| Zatovicova, M | 1 |
| Pastorekova, S | 1 |
| Safa Shams Abyaneh, F | 1 |
| Eslami Moghadam, M | 1 |
| Hossaini Sadr, M | 1 |
| Divsalar, A | 1 |
| Sullivan, MR | 1 |
| Vander Heiden, MG | 1 |
| Archambault, V | 1 |
| Normandin, K | 1 |
| Amelio, I | 3 |
| Melino, G | 3 |
| Frezza, C | 1 |
| Wan Makhtar, WR | 1 |
| Browne, G | 1 |
| Karountzos, A | 1 |
| Stevens, C | 1 |
| Alghamdi, Y | 1 |
| Bottrill, AR | 1 |
| Mistry, S | 1 |
| Smith, E | 1 |
| Bushel, M | 1 |
| Pringle, JH | 1 |
| Sayan, AE | 1 |
| Tulchinsky, E | 1 |
| Hanley, MJ | 4 |
| Venkatakrishnan, K | 6 |
| Bessudo, A | 2 |
| Rasco, DW | 1 |
| Sharma, S | 3 |
| O'Neil, BH | 1 |
| Liu, G | 3 |
| Ke, A | 1 |
| Patel, C | 1 |
| Rowland Yeo, K | 1 |
| Xia, C | 3 |
| Zhang, X | 4 |
| Esseltine, DL | 1 |
| Nemunaitis, J | 3 |
| Pusalkar, S | 2 |
| Plesescu, M | 2 |
| Chowdhury, S | 2 |
| Shepard, DR | 1 |
| Andreotti, G | 2 |
| Koutros, S | 2 |
| Hofmann, JN | 2 |
| Sandler, DP | 3 |
| Lubin, JH | 2 |
| Lynch, CF | 2 |
| Lerro, CC | 2 |
| De Roos, AJ | 3 |
| Parks, CG | 2 |
| Alavanja, MC | 2 |
| Silverman, DT | 2 |
| Beane Freeman, LE | 2 |
| Ward, EM | 1 |
| Infante, PF | 1 |
| Melnick, R | 1 |
| Vainio, H | 2 |
| Huff, J | 2 |
| Park, JE | 1 |
| Miller, Z | 1 |
| Jun, Y | 1 |
| Lee, W | 1 |
| Kim, KB | 1 |
| Davoren, MJ | 1 |
| Schiestl, RH | 1 |
| Hanley, M | 1 |
| Wu, JT | 1 |
| Sowers, ML | 1 |
| Herring, J | 1 |
| Tang, H | 1 |
| Ou, Y | 1 |
| Gu, W | 1 |
| Zhang, K | 1 |
| Pandey, B | 1 |
| Patil, NG | 1 |
| Bhosle, GS | 1 |
| Ambade, AV | 1 |
| Gupta, SS | 1 |
| Sheppard, L | 1 |
| Shaffer, RM | 1 |
| Jin, P | 1 |
| Sha, R | 1 |
| Bian, Y | 1 |
| Qian, J | 2 |
| Ishimwe, N | 1 |
| Hu, Y | 3 |
| Yin, S | 1 |
| Wen, LP | 1 |
| Guo, T | 1 |
| Qiu, Y | 1 |
| Chen, X | 2 |
| Song, J | 1 |
| Yang, H | 4 |
| Cherukula, K | 1 |
| Uthaman, S | 1 |
| Park, IK | 1 |
| Fan, B | 1 |
| Mellinghoff, IK | 1 |
| Wen, PY | 1 |
| Lowery, MA | 1 |
| Goyal, L | 1 |
| Tap, WD | 1 |
| Pandya, SS | 1 |
| Manyak, E | 1 |
| Jiang, L | 1 |
| Nimkar, T | 1 |
| Gliser, C | 1 |
| Prahl Judge, M | 1 |
| Agresta, S | 1 |
| Dai, D | 1 |
| Samet, JM | 1 |
| Morabia, A | 1 |
| Arjó, G | 1 |
| Portero, M | 1 |
| Piñol, C | 1 |
| Viñas, J | 1 |
| Matias-Guiu, X | 1 |
| Capell, T | 1 |
| Bartholomaeus, A | 1 |
| Parrott, W | 1 |
| Christou, P | 1 |
| Zhang, J | 1 |
| Wu, P | 1 |
| Ghosh, RD | 1 |
| Banerjee, K | 1 |
| Ganguly, A | 2 |
| Chakraborty, P | 2 |
| Sarkar, A | 1 |
| Chatterjee, M | 2 |
| Choudhuri, SK | 2 |
| Aljahdali, M | 1 |
| Locasale, JW | 2 |
| Ham, DJ | 1 |
| Murphy, KT | 1 |
| Chee, A | 1 |
| Lynch, GS | 1 |
| Koopman, R | 1 |
| Fan, AC | 1 |
| O'Rourke, JJ | 1 |
| Praharaj, DR | 1 |
| Felsher, DW | 1 |
| Li, Q | 1 |
| Lambrechts, MJ | 1 |
| Zhang, Q | 1 |
| Liu, S | 3 |
| Ge, D | 1 |
| Yin, R | 1 |
| Xi, M | 1 |
| You, Z | 1 |
| Tedeschi, PM | 2 |
| Markert, EK | 1 |
| Gounder, M | 1 |
| Dvorzhinski, D | 1 |
| Dolfi, SC | 1 |
| Chan, LL | 1 |
| Qiu, J | 1 |
| DiPaola, RS | 1 |
| Hirshfield, KM | 1 |
| Boros, LG | 1 |
| Bertino, JR | 2 |
| Oltvai, ZN | 1 |
| Vazquez, A | 3 |
| Bowles, DW | 1 |
| Diamond, JR | 1 |
| Lam, ET | 1 |
| Weekes, CD | 2 |
| Astling, DP | 1 |
| Anderson, RT | 1 |
| Leong, S | 1 |
| Gore, L | 1 |
| Varella-Garcia, M | 1 |
| Vogler, BW | 1 |
| Keysar, SB | 1 |
| Freas, E | 1 |
| Aisner, DL | 1 |
| Ren, C | 2 |
| Tan, AC | 1 |
| Wilhelm, F | 2 |
| Maniar, M | 3 |
| Eckhardt, SG | 2 |
| Messersmith, WA | 3 |
| Jimeno, A | 3 |
| Kwiatkowska, M | 1 |
| Paweł, J | 1 |
| Bukowska, B | 2 |
| Cutruzzolá, F | 1 |
| Antonov, A | 2 |
| Agostini, M | 2 |
| van den Broek, NJ | 1 |
| Mackay, GM | 1 |
| Maddocks, OD | 1 |
| Yagi, H | 1 |
| Allegra, R | 1 |
| Tunesi, S | 1 |
| Cilia, R | 1 |
| Pezzoli, G | 1 |
| Goldwurm, S | 1 |
| Liu, T | 1 |
| Luo, S | 1 |
| Tan, X | 1 |
| Qi, Q | 1 |
| Shi, C | 1 |
| Infante, JR | 2 |
| Weiss, GJ | 1 |
| Jones, S | 1 |
| Tibes, R | 1 |
| Bauer, TM | 1 |
| Bendell, JC | 1 |
| Hinson, JM | 1 |
| Von Hoff, DD | 1 |
| Burris, HA | 1 |
| Orlemans, EO | 1 |
| Ramanathan, RK | 1 |
| Lu, T | 1 |
| Laughton, CA | 1 |
| Bradshaw, TD | 1 |
| Agalliu, I | 1 |
| San Luciano, M | 1 |
| Mirelman, A | 1 |
| Giladi, N | 1 |
| Waro, B | 1 |
| Aasly, J | 1 |
| Inzelberg, R | 1 |
| Hassin-Baer, S | 1 |
| Friedman, E | 1 |
| Ruiz-Martinez, J | 1 |
| Marti-Masso, JF | 1 |
| Orr-Urtreger, A | 1 |
| Bressman, S | 1 |
| Saunders-Pullman, R | 1 |
| Morello, M | 1 |
| Minieri, M | 1 |
| Mehrmohamadi, M | 1 |
| Liu, X | 1 |
| Shestov, AA | 1 |
| Jiang, G | 1 |
| Yin, F | 2 |
| Duan, J | 1 |
| Li, G | 1 |
| Mitsiades, CS | 1 |
| Smith, DC | 1 |
| Kalebic, T | 1 |
| Siu, LL | 1 |
| Sullivan, D | 1 |
| Vlahovic, G | 1 |
| Kauh, JS | 1 |
| Gao, F | 1 |
| Berger, AJ | 1 |
| Tirrell, S | 1 |
| Di Bacco, A | 1 |
| Berg, D | 1 |
| Hui, AM | 3 |
| Thompson, JA | 1 |
| Guyton, KZ | 1 |
| Loomis, D | 1 |
| Grosse, Y | 1 |
| El Ghissassi, F | 1 |
| Benbrahim-Tallaa, L | 1 |
| Guha, N | 1 |
| Scoccianti, C | 1 |
| Mattock, H | 1 |
| Straif, K | 1 |
| Huh, Y | 1 |
| Hutmacher, MM | 1 |
| Ottinger, S | 1 |
| Jerbi, S | 1 |
| Jolles, B | 1 |
| Bouceba, T | 1 |
| Jean-Jean, O | 1 |
| Portier, CJ | 1 |
| Armstrong, BK | 1 |
| Baguley, BC | 1 |
| Baur, X | 1 |
| Belyaev, I | 1 |
| Bellé, R | 1 |
| Belpoggi, F | 1 |
| Biggeri, A | 1 |
| Bosland, MC | 1 |
| Bruzzi, P | 1 |
| Budnik, LT | 1 |
| Bugge, MD | 1 |
| Burns, K | 1 |
| Calaf, GM | 1 |
| Carpenter, DO | 1 |
| Carpenter, HM | 1 |
| López-Carrillo, L | 1 |
| Clapp, R | 1 |
| Cocco, P | 1 |
| Consonni, D | 1 |
| Comba, P | 1 |
| Craft, E | 1 |
| Dalvie, MA | 1 |
| Davis, D | 1 |
| Demers, PA | 1 |
| DeWitt, J | 1 |
| Forastiere, F | 1 |
| Freedman, JH | 1 |
| Fritschi, L | 1 |
| Gaus, C | 1 |
| Gohlke, JM | 1 |
| Goldberg, M | 1 |
| Greiser, E | 1 |
| Hansen, J | 1 |
| Hardell, L | 1 |
| Hauptmann, M | 1 |
| Huang, W | 1 |
| James, MO | 1 |
| Jameson, CW | 1 |
| Kortenkamp, A | 1 |
| Kopp-Schneider, A | 1 |
| Kromhout, H | 1 |
| Larramendy, ML | 1 |
| Landrigan, PJ | 1 |
| Lash, LH | 1 |
| Leszczynski, D | 1 |
| Magnani, C | 1 |
| Mandrioli, D | 1 |
| Martin, FL | 1 |
| Merler, E | 1 |
| Michelozzi, P | 1 |
| Miligi, L | 1 |
| Miller, AB | 1 |
| Mirabelli, D | 1 |
| Mirer, FE | 1 |
| Naidoo, S | 1 |
| Perry, MJ | 1 |
| Petronio, MG | 1 |
| Pirastu, R | 1 |
| Portier, RJ | 1 |
| Ramos, KS | 1 |
| Robertson, LW | 1 |
| Rodriguez, T | 1 |
| Röösli, M | 1 |
| Ross, MK | 1 |
| Roy, D | 1 |
| Saldiva, P | 1 |
| Sass, J | 1 |
| Savolainen, K | 1 |
| Scheepers, PT | 1 |
| Sergi, C | 1 |
| Silbergeld, EK | 1 |
| Smith, MT | 1 |
| Stewart, BW | 1 |
| Sutton, P | 1 |
| Tateo, F | 1 |
| Terracini, B | 1 |
| Thielmann, HW | 1 |
| Thomas, DB | 1 |
| Vena, JE | 1 |
| Vineis, P | 1 |
| Weiderpass, E | 1 |
| Weisenburger, DD | 1 |
| Woodruff, TJ | 1 |
| Yorifuji, T | 1 |
| Yu, IJ | 1 |
| Zambon, P | 1 |
| Zeeb, H | 1 |
| Zhou, SF | 1 |
| Chang, ET | 1 |
| Delzell, E | 1 |
| Meiser, J | 1 |
| Perez, R | 1 |
| Norris, RE | 1 |
| Qian, MG | 1 |
| Falchook, G | 1 |
| Labotka, R | 1 |
| Pérez-Torres, I | 1 |
| Zuniga-Munoz, AM | 1 |
| Guarner-Lans, V | 1 |
| Schulte-Wissermann, H | 1 |
| Tarone, RE | 1 |
| Gu, H | 1 |
| Carroll, PA | 1 |
| Du, J | 1 |
| Zhu, J | 1 |
| Neto, FC | 1 |
| Eisenman, RN | 1 |
| Raftery, D | 1 |
| Bus, JS | 1 |
| Laheru, D | 1 |
| Rudek, MA | 1 |
| Hidalgo, M | 1 |
| Baker, SD | 1 |
| Donehower, RC | 1 |
| Niu, G | 1 |
| Shi, J | 1 |
| Wang, F | 1 |
| Lao, VV | 1 |
| Herring, JL | 1 |
| Kim, CH | 1 |
| Darwanto, A | 1 |
| Soto, U | 1 |
| Sowers, LC | 1 |
| Ierano, C | 1 |
| Giuliano, P | 1 |
| D'Alterio, C | 1 |
| Cioffi, M | 1 |
| Mettivier, V | 1 |
| Portella, L | 1 |
| Napolitano, M | 1 |
| Barbieri, A | 1 |
| Arra, C | 1 |
| Liguori, G | 1 |
| Franco, R | 1 |
| Palmieri, G | 1 |
| Rozzo, C | 1 |
| Pacelli, R | 1 |
| Castello, G | 1 |
| Scala, S | 1 |
| Li, L | 1 |
| Huang, X | 1 |
| Huo, K | 1 |
| Schöffski, P | 1 |
| Reid, AH | 1 |
| Protheroe, A | 1 |
| Attard, G | 1 |
| Hayward, N | 1 |
| Vidal, L | 1 |
| Spicer, J | 1 |
| Shaw, HM | 1 |
| Bone, EA | 2 |
| Carter, J | 1 |
| Hooftman, L | 2 |
| Harris, A | 1 |
| De Bono, JS | 1 |
| Kupperman, E | 1 |
| Lee, EC | 1 |
| Cao, Y | 1 |
| Bannerman, B | 1 |
| Fitzgerald, M | 1 |
| Berger, A | 1 |
| Yang, Y | 1 |
| Hales, P | 1 |
| Bruzzese, F | 1 |
| Liu, J | 1 |
| Blank, J | 1 |
| Garcia, K | 1 |
| Tsu, C | 1 |
| Dick, L | 1 |
| Fleming, P | 1 |
| Yu, L | 1 |
| Rolfe, M | 1 |
| Bolen, J | 1 |
| Konkimalla, VB | 1 |
| Efferth, T | 1 |
| Voĭtenkov, VB | 1 |
| Popovich, IG | 1 |
| Zabezhinskiĭ, MA | 1 |
| Iurova, MA | 1 |
| Piskunova, TA | 1 |
| Mikhaleva, II | 1 |
| van Herpen, CM | 1 |
| Eskens, FA | 1 |
| de Jonge, M | 1 |
| Desar, I | 1 |
| Timmer-Bonte, JN | 1 |
| Verweij, J | 1 |
| Wickström, M | 1 |
| Larsson, R | 1 |
| Nygren, P | 1 |
| Gullbo, J | 1 |
| Rajan, A | 1 |
| Kelly, RJ | 1 |
| Trepel, JB | 1 |
| Kim, YS | 1 |
| Alarcon, SV | 1 |
| Kummar, S | 1 |
| Gutierrez, M | 1 |
| Crandon, S | 1 |
| Zein, WM | 1 |
| Jain, L | 1 |
| Mannargudi, B | 1 |
| Figg, WD | 1 |
| Houk, BE | 1 |
| Shnaidman, M | 1 |
| Brega, N | 1 |
| Giaccone, G | 1 |
| Dadwal, M | 1 |
| Kang, CS | 1 |
| Song, HA | 1 |
| Sun, X | 1 |
| Dai, A | 1 |
| Baidoo, KE | 1 |
| Brechbiel, MW | 1 |
| Chong, HS | 1 |
| Zhang, WC | 1 |
| Shyh-Chang, N | 1 |
| Umashankar, S | 1 |
| Ma, S | 1 |
| Soh, BS | 1 |
| Sun, LL | 1 |
| Tai, BC | 1 |
| Nga, ME | 1 |
| Bhakoo, KK | 1 |
| Jayapal, SR | 1 |
| Nichane, M | 1 |
| Yu, Q | 1 |
| Ahmed, DA | 1 |
| Tan, C | 1 |
| Sing, WP | 1 |
| Tam, J | 1 |
| Thirugananam, A | 1 |
| Noghabi, MS | 1 |
| Pang, YH | 1 |
| Ang, HS | 1 |
| Mitchell, W | 1 |
| Robson, P | 1 |
| Kaldis, P | 1 |
| Soo, RA | 1 |
| Swarup, S | 1 |
| Lim, EH | 1 |
| Lim, B | 1 |
| Mullard, A | 1 |
| Chatterjee, S | 1 |
| Saha, P | 1 |
| Adhikary, A | 1 |
| Das, T | 1 |
| Elliott, MA | 1 |
| Ford, SJ | 1 |
| Prasad, E | 1 |
| Dick, LJ | 1 |
| Farmer, H | 1 |
| Hogg, PJ | 1 |
| Halbert, GW | 1 |
| Ma, WW | 1 |
| Dy, GK | 1 |
| Whitworth, A | 1 |
| Adjei, AA | 1 |
| Cho, JK | 1 |
| Chun, C | 1 |
| Kuh, HJ | 1 |
| Song, SC | 1 |
| Tomita, M | 1 |
| Kami, K | 1 |
| Jain, M | 1 |
| Nilsson, R | 1 |
| Madhusudhan, N | 1 |
| Kitami, T | 1 |
| Souza, AL | 1 |
| Kafri, R | 1 |
| Kirschner, MW | 1 |
| Clish, CB | 1 |
| Mootha, VK | 1 |
| Mink, PJ | 1 |
| Mandel, JS | 1 |
| Sceurman, BK | 1 |
| Lundin, JI | 1 |
| Lan, R | 1 |
| Lin, G | 1 |
| Wang, J | 1 |
| Gong, J | 1 |
| Ding, YH | 1 |
| Yang, Z | 1 |
| Lu, F | 1 |
| Lassila, R | 1 |
| Fernández, A | 1 |
| Roth, E | 1 |
| Zellner, M | 1 |
| Wessner, B | 1 |
| Strasser, E | 1 |
| Manhart, N | 1 |
| Oehler, R | 1 |
| Spittler, A | 1 |
| LEPAGE, GA | 7 |
| TYNER, EP | 2 |
| HEIDELBERGER, C | 2 |
| FORSSBERG, A | 2 |
| KLEIN, G | 1 |
| HEINZ, E | 3 |
| BARCLAY, RK | 1 |
| GARFINKEL, E | 1 |
| KIT, S | 5 |
| GRAHAM, OL | 2 |
| GRUZDEVA, KN | 1 |
| COLTER, JS | 1 |
| KRITCHEVSKY, D | 1 |
| BIRD, HH | 1 |
| MCCANDLESS, RF | 1 |
| MARIANI, HA | 1 |
| WILLIAMS, AM | 1 |
| BLECHER, M | 1 |
| WHITE, A | 1 |
| HARMON, DH | 1 |
| KIRK, MR | 1 |
| TOLBERT, BM | 1 |
| FINLAYSON, JS | 1 |
| DREYFUS, G | 1 |
| SPRIGGS, AI | 1 |
| LAJTHA, LG | 1 |
| COLES, NW | 1 |
| JOHNSTONE, RM | 2 |
| QUASTEL, JH | 1 |
| COSTAKEL, O | 1 |
| KITULESCO, I | 1 |
| VOICULET, N | 1 |
| POPP, I | 1 |
| HEMPLING, HG | 1 |
| HARE, D | 1 |
| ELLIS, DB | 1 |
| SCHOLEFIELD, PG | 2 |
| ROOF, BS | 1 |
| RYSER, H | 1 |
| AUB, JC | 1 |
| BARTHOLOMEW, ME | 1 |
| TUPPER, R | 1 |
| WORMALL, A | 1 |
| ZBARSKII, IB | 1 |
| KARUZINA, NP | 1 |
| GITTERMAN, CO | 3 |
| DULANEY, EL | 3 |
| KACZKA, EA | 3 |
| HENDLIN, D | 2 |
| WOODRUFF, HB | 2 |
| HASCHEN, RJ | 1 |
| SCHINDLER, R | 1 |
| CHAUBE, S | 1 |
| MURPHY, ML | 1 |
| DE GREGORIO, P | 1 |
| HARRIS, JJ | 1 |
| TELLER, MN | 1 |
| YAP-GUEVARA, E | 1 |
| WOOLLEY, GW | 1 |
| GRECO, AV | 1 |
| CECCHI, F | 1 |
| CARBONIN, PU | 1 |
| SENSI, S | 1 |
| GAMBASSI, G | 1 |
| WU, C | 1 |
| BAUER, JM | 1 |
| WAGLE, SR | 1 |
| ASHMORE, J | 1 |
| LEVINE, AS | 1 |
| MELONI, GA | 1 |
| GENTY, N | 1 |
| VENDRELY, R | 1 |
| TERRANOVA, T | 2 |
| FEO, F | 2 |
| GRAVELA, E | 2 |
| GABRIEL, L | 2 |
| VANPILSUM, JF | 1 |
| WARHOL, RM | 1 |
| BECKMAN, D | 1 |
| BOLINE, J | 1 |
| CHRISTENSEN, HN | 1 |
| BORENFREUND, E | 1 |
| KRIM, M | 1 |
| BENDICH, A | 1 |
| RYAN, WL | 1 |
| LORINCZ, AB | 1 |
| CAMPBELL, GW | 1 |
| PRADHAN, SN | 1 |
| WEST, WL | 1 |
| BENNETT, LL | 1 |
| SMITHERS, D | 1 |
| WARD, CT | 1 |
| GORDON, JE | 1 |
| WOOLFREY, BF | 1 |
| DELOECKER, W | 2 |
| ATCHLEY, WA | 1 |
| BHAGAVAN, NV | 1 |
| FOELSCH, E | 1 |
| DREWS, J | 1 |
| GRUNZE, H | 1 |
| PAN, JC | 1 |
| HO, S | 1 |
| CHEN, CK | 1 |
| BAI, YC | 1 |
| HORKY, J | 1 |
| PLACER, Z | 1 |
| SHIGEURA, HT | 1 |
| GORDON, CN | 1 |
| MORSE, PA | 1 |
| POTTER, VR | 1 |
| DUNN, WL | 1 |
| LOCKNER, D | 1 |
| ERICSON, U | 1 |
| HEVESY, G | 1 |
| EDMONDS, MP | 1 |
| GREENLEES, JL | 1 |
| GREENLEES, J | 1 |
| MINOWADA, J | 1 |
| FOLKERS, K | 1 |
| NORBERG, E | 1 |
| GREENBERG, DM | 3 |
| FARBER, E | 1 |
| LOCKETT, MF | 1 |
| EVANS, MM | 1 |
| Mikawa, M | 1 |
| Guo, L | 1 |
| Liu, R | 1 |
| Marik, J | 1 |
| Takada, Y | 1 |
| Lam, K | 1 |
| Lau, D | 1 |
| Blair, A | 1 |
| Rusiecki, JA | 1 |
| Hoppin, JA | 1 |
| Svec, M | 1 |
| Dosemeci, M | 1 |
| Powis, G | 1 |
| Wipf, P | 1 |
| Lynch, SM | 1 |
| Birmingham, A | 1 |
| Kirkpatrick, DL | 1 |
| von Guggenberg, E | 1 |
| Dietrich, H | 1 |
| Skvortsova, I | 1 |
| Gabriel, M | 1 |
| Virgolini, IJ | 1 |
| Decristoforo, C | 1 |
| Xiong, XB | 1 |
| Mahmud, A | 1 |
| Uludağ, H | 1 |
| Lavasanifar, A | 1 |
| Tannehill-Gregg, SH | 1 |
| Sanderson, TP | 1 |
| Minnema, D | 1 |
| Voelker, R | 1 |
| Ulland, B | 1 |
| Cohen, SM | 1 |
| Arnold, LL | 1 |
| Schilling, BE | 1 |
| Waites, CR | 1 |
| Dominick, MA | 1 |
| Teng, B | 1 |
| Bai, Y | 1 |
| Chang, Y | 1 |
| Chen, S | 1 |
| Avdievich, E | 1 |
| Reiss, C | 1 |
| Scherer, SJ | 1 |
| Maier, SM | 1 |
| Jin, B | 1 |
| Hou, H | 1 |
| Rosenwald, A | 1 |
| Riedmiller, H | 1 |
| Kucherlapati, R | 1 |
| Cohen, PE | 1 |
| Edelmann, W | 1 |
| Kneitz, B | 1 |
| Heckmann, D | 1 |
| Meyer, A | 1 |
| Laufer, B | 1 |
| Zahn, G | 1 |
| Stragies, R | 1 |
| Kessler, H | 1 |
| Lembach, K | 2 |
| Charalampous, FC | 2 |
| Fairchild, RG | 1 |
| Bond, VP | 1 |
| Stein, TP | 2 |
| Ang, SD | 1 |
| Schluter, MD | 1 |
| Leskiw, MJ | 1 |
| Nusbaum, M | 1 |
| Levin, L | 1 |
| Gevers, W | 1 |
| Jardine, L | 1 |
| De Guel, FJ | 1 |
| Duncan, EJ | 1 |
| Královec, J | 1 |
| Krepelka, J | 1 |
| Norton, JA | 1 |
| Brennan, MF | 3 |
| Kamada, S | 1 |
| Maeda, M | 1 |
| Tsuji, A | 1 |
| Poster, DS | 1 |
| Bruno, S | 1 |
| Penta, J | 1 |
| Neil, GL | 1 |
| McGovren, JP | 1 |
| Taylor, CR | 1 |
| Shi, SR | 1 |
| Chaiwun, B | 1 |
| Young, L | 1 |
| Imam, SA | 1 |
| Cote, RJ | 1 |
| Brugières, L | 1 |
| Gardes, M | 1 |
| Moutou, C | 1 |
| Chompret, A | 1 |
| Meresse, V | 1 |
| Martin, A | 1 |
| Poisson, N | 1 |
| Flamant, F | 1 |
| Bonaïti-Pellié, C | 1 |
| Lemerle, J | 1 |
| Hjelstuen, OK | 1 |
| Maelandsmo, GM | 1 |
| Tønnesen, HH | 1 |
| Bremmer, PO | 1 |
| Verbruggen, AM | 1 |
| Renwick, SB | 1 |
| Snell, K | 1 |
| Baumann, U | 1 |
| Ruediger, R | 1 |
| Pham, HT | 1 |
| Walter, G | 1 |
| Van Aken, H | 1 |
| Bode, C | 1 |
| Darius, H | 1 |
| Diehm, C | 1 |
| Encke, A | 1 |
| Gulba, DC | 1 |
| Haas, S | 1 |
| Hacke, W | 1 |
| Puhl, W | 1 |
| Quante, M | 1 |
| Riess, H | 1 |
| Scharf, R | 1 |
| Schellong, S | 1 |
| Schrör, T | 1 |
| Schulte, KL | 1 |
| Tebbe, U | 1 |
| Tanaka, T | 1 |
| Nakajima, T | 1 |
| Nagata, K | 1 |
| Suzuki, T | 1 |
| Okano, Y | 1 |
| Hamaguchi, M | 1 |
| Nozawa, Y | 1 |
| Jeevanandam, M | 2 |
| Lowry, SF | 2 |
| Horowitz, GD | 1 |
| Rose, D | 1 |
| Mihranian, MH | 1 |
| Daly, J | 1 |
| Discombe, G | 1 |
| Lund, S | 1 |
| Shimizu, T | 2 |
| Bottici, R | 1 |
| Ferrucci, A | 1 |
| Taddeucci, E | 1 |
| Harrison, HE | 1 |
| Tiollais, P | 1 |
| Björnesjö, KB | 2 |
| Jarnulf, B | 1 |
| Lausing, E | 1 |
| Pisani, W | 1 |
| Bonzanino, A | 1 |
| Franco, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1 Study of Oral IXAZOMIB (MLN9708) to Assess Relative Bioavailability, Food Effect, Drug-Drug Interaction With Ketoconazole, Clarithromycin or Rifampin; and Safety and Tolerability in Patients With Advanced Nonhematologic Malignancies or Lymphoma[NCT01454076] | Phase 1 | 112 participants (Actual) | Interventional | 2011-11-10 | Completed | ||
| A Phase 1 Study of [ 14 C]-Ixazomib to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients With Advanced Solid Tumors or Lymphoma[NCT01953783] | Phase 1 | 7 participants (Actual) | Interventional | 2014-03-19 | Completed | ||
| A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation[NCT02073994] | Phase 1 | 170 participants (Anticipated) | Interventional | 2014-03-01 | Active, not recruiting | ||
| Phase II Study of Paclitaxel and TAK-228 in Metastatic Urothelial Carcinoma (UC) and the Impact of PI3K-mTOR Pathway Genomic Alterations[NCT03745911] | Phase 2 | 52 participants (Anticipated) | Interventional | 2018-05-04 | Recruiting | ||
| Phase II Single-arm Study of ON 01910.Na by 2-hr Infusion in Patients With Recurring Platinum-resistant Ovarian Cancer[NCT00856791] | Phase 2 | 1 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Phase I Dose Escalation Study of Gemcitabine and ON 01910.Na in Patients With Advanced or Metastatic Solid Tumors[NCT01125891] | Phase 1 | 39 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Phase III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined With Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Cancer[NCT01360853] | Phase 3 | 160 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| A Phase 1/2, Single-Arm Study To Assess The Efficacy and Safety Of 72-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Every Other Week in Patients With Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)[NCT00854945] | Phase 1/Phase 2 | 36 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Phase 1 Dose-Escalation Study of the Safety and Clinical Effects of ON 01910.Na in Combination With Either Irinotecan or Oxaliplatin in Patients With Advanced Solid Tumors[NCT00861328] | Phase 1 | 18 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Phase 1 Dose-Escalation Study of the Safety and Clinical Effects of ON 01910.Na in Combination With Either Irinotecan or Oxaliplatin in Patients With Hepatoma and Other Advanced Solid Tumors[NCT00861783] | Phase 1 | 16 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01454076)
Timeframe: Arm 1:Days 1, 15 and Arm 5:Day 6 pre-dose and at multiple time points(up to 264 hrs)post-dose;Arm 2, 3:Days 1,15 pre-dose and at multiple time points(up to 216 hrs)post-dose;Arm 4:Day 8 pre-dose and at multiple time points(up to 168 hrs)post-dose
| Intervention | nanogram*hour per milliliter (ng*hr/mL)] (Geometric Mean) |
|---|---|
| Arm 1: Ixazomib 2.5 mg | 551.985 |
| Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg | 1148.778 |
| Arm 2: Ixazomib 4 mg Capsule A | 1284.079 |
| Arm 2: Ixazomib 4 mg Capsule B | 1334.659 |
| Arm 3: Ixazomib 4 mg Fasted | 1465.979 |
| Arm 3: Ixazomib 4 mg Fed | 998.698 |
| Arm 4: Ixazomib 4 mg + Rifampin 600 mg | 231.527 |
| Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg | 613.112 |
(NCT01454076)
Timeframe: Arm 1:Days 1, 15 and Arm 5:Day 6 pre-dose and at multiple time points(up to 264 hours[hrs])post-dose;Arm 2, 3:Days 1,15 pre-dose and at multiple time points(up to 216 hrs)post-dose;Arm 4:Day 8 pre-dose and at multiple time points(up to 168 hrs)post-dose
| Intervention | nanogram per milliliter (ng/mL) (Geometric Mean) |
|---|---|
| Arm 1: Ixazomib 2.5 mg | 38.975 |
| Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg | 39.250 |
| Arm 2: Ixazomib 4 mg Capsule A | 61.866 |
| Arm 2: Ixazomib 4 mg Capsule B | 71.949 |
| Arm 3: Ixazomib 4 mg Fasted | 77.001 |
| Arm 3: Ixazomib 4 mg Fed | 22.752 |
| Arm 4: Ixazomib 4 mg + Rifampin 600 mg | 25.706 |
| Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg | 37.245 |
(NCT01454076)
Timeframe: Cycle 1 Day 1 up to 30 days after last dose of study drug (Arm 1 and 5: Cycle 19 Day 45; Arm 2: Cycle 7 Day 45; Arm 3: Cycle 22 Day 45; Arm 4: Cycle 25 Day 45
| Intervention | participants (Number) |
|---|---|
| Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg | 0 |
| Arm 2: Ixazomib 4 mg Capsule A or B | 0 |
| Arm 3: Ixazomib 4 mg Fasted or Fed | 0 |
| Arm 4: Ixazomib 4 mg + Rifampin 600 mg | 0 |
| Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg | 0 |
(NCT01454076)
Timeframe: Arm 1:Days 1, 15 and Arm 5:Day 6 pre-dose and at multiple time points(up to 264 hrs)post-dose;Arm 2, 3:Days 1,15 pre-dose and at multiple time points(up to 216 hrs)post-dose;Arm 4:Day 8 pre-dose and at multiple time points(up to 168 hrs)post-dose
| Intervention | hours (Median) |
|---|---|
| Arm 1: Ixazomib 2.5 mg | 1.090 |
| Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg | 1.500 |
| Arm 2: Ixazomib 4 mg Capsule A | 1.290 |
| Arm 2: Ixazomib 4 mg Capsule B | 1.250 |
| Arm 3: Ixazomib 4 mg Fasted | 1.020 |
| Arm 3: Ixazomib 4 mg Fed | 4.000 |
| Arm 4: Ixazomib 4 mg + Rifampin 600 mg | 1.450 |
| Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg | 1 |
(NCT01454076)
Timeframe: Cycle 1 Day 1 up to 30 days after last dose of study drug (Arm 1 and 5: Cycle 19 Day 45; Arm 2: Cycle 7 Day 45; Arm 3: Cycle 22 Day 45; Arm 4: Cycle 25 Day 45)
| Intervention | participants (Number) | |
|---|---|---|
| TEAEs | SAEs | |
| Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg | 29 | 12 |
| Arm 2: Ixazomib 4 mg Capsule A or B | 20 | 5 |
| Arm 3: Ixazomib 4 mg Fasted or Fed | 24 | 12 |
| Arm 4: Ixazomib 4 mg + Rifampin 600 mg | 18 | 3 |
| Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg | 21 | 10 |
(NCT01454076)
Timeframe: Cycle 1 Day 1 up to 30 days after last dose of study drug (Arm 1 and 5: Cycle 19 Day 45; Arm 2: Cycle 7 Day 45; Arm 3: Cycle 22 Day 45; Arm 4: Cycle 25 Day 45
| Intervention | participants (Number) | ||
|---|---|---|---|
| Blood and lymphatic system disorders | Investigations | Metabolism and nutrition disorders | |
| Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg | 11 | 10 | 22 |
| Arm 2: Ixazomib 4 mg Capsule A or B | 7 | 5 | 12 |
| Arm 3: Ixazomib 4 mg Fasted or Fed | 9 | 11 | 13 |
| Arm 4: Ixazomib 4 mg + Rifampin 600 mg | 2 | 4 | 6 |
| Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg | 1 | 5 | 6 |
Best overall response for a participant is best observed post-baseline disease response as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1: Complete response (CR) was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than (<) 10 millimeter [mm]). No new lesions. Partial response (PR) was defined as greater than or equal to (>=) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. Stable disease (SD) was defined as not qualifying for CR, PR, Progressive Disease (PD). An increase of >=20% from the nadir (or baseline, if it represents the point at which the sum of target disease was lowest) represents PD. (NCT01454076)
Timeframe: Baseline up to end of treatment (approximately 1.9 years)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| CR | PR | SD | PD | |
| Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg | 0 | 0 | 63 | 38 |
| Arm 2: Ixazomib 4 mg Capsule A or B | 0 | 0 | 50 | 50 |
| Arm 3: Ixazomib 4 mg Fasted or Fed | 0 | 6 | 35 | 59 |
| Arm 4: Ixazomib 4 mg + Rifampin 600 mg | 0 | 0 | 53 | 47 |
| Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg | 0 | 1 | 53 | 47 |
Vital signs included oral body temperature, heart rate, and blood pressure. (NCT01953783)
Timeframe: Baseline up to Cycle 5 Day 25
| Intervention | participants (Number) |
|---|---|
| Ixazomib | 0 |
AUC(0-312) is a measure of the area under the plasma concentration time-curve from time zero to 312 hrs post-dose for ixazomib. (NCT01953783)
Timeframe: Day 1 of Part A pre-dose and at multiple timepoints (up to 312 hrs) post-dose
| Intervention | nanogram*hour per milliliter (ng*hr/mL) (Geometric Mean) |
|---|---|
| Ixazomib | 1181 |
AUC(0-816) is a measure of the area under the plasma concentration time-curve from time zero to 816 hrs post-dose for TRA. (NCT01953783)
Timeframe: Day 1 of Part A pre-dose and at multiple timepoints (up to 816 hrs) post-dose
| Intervention | nanogram-equivalent*hour per milliliter (Geometric Mean) |
|---|---|
| Ixazomib | 2981 |
AUC(0-816) is a measure of the area under the whole blood concentration time-curve from time zero to 816 hrs post-dose for TRA. (NCT01953783)
Timeframe: Day 1 of Part A pre-dose and at multiple timepoints (up to 816 hrs) post-dose
| Intervention | nanogram-equivalent* hour per milliliter (Geometric Mean) |
|---|---|
| Ixazomib | 29200 |
Maximum observed plasma concentration (Cmax) is the peak plasma concentration of ixazomib, obtained directly from the plasma concentration-time curve. (NCT01953783)
Timeframe: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 14) post-dose
| Intervention | nanogram per milliliter (ng/mL) (Geometric Mean) |
|---|---|
| Ixazomib | 89.06 |
Maximum observed plasma concentration (Cmax) of TRA is the peak plasma concentration of TRA, obtained directly from the plasma TRA concentration-time curve. (NCT01953783)
Timeframe: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
| Intervention | nanogram-equivalent per milliliter (Geometric Mean) |
|---|---|
| Ixazomib | 78.80 |
Maximum observed whole blood concentration (Cmax) of a TRA is the peak whole blood concentration of TRA, obtained directly from the whole blood TRA concentration-time curve. (NCT01953783)
Timeframe: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
| Intervention | nanogram-equivalent per milliliter (Geometric Mean) |
|---|---|
| Ixazomib | 181.6 |
Percentage of the ixazomib dose excreted unchanged in the urine from 0 to 168 hrs post-dose. (NCT01953783)
Timeframe: Day 1 of Part A from 0 to pre-dose and at multiple timepoints (up to 168 hrs) post-dose
| Intervention | percentage of dose (Mean) |
|---|---|
| Ixazomib | 3.226 |
Percentage of the TRA dose excreted in feces from Day 1 to Day 35 of Part A (NCT01953783)
Timeframe: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
| Intervention | percentage of dose (Mean) |
|---|---|
| Ixazomib | 21.80 |
Percentage of the TRA dose excreted in urine from Day 1 to Day 35 of Part A. (NCT01953783)
Timeframe: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
| Intervention | percentage of dose (Mean) |
|---|---|
| Ixazomib | 62.06 |
Renal clearance is the volume of plasma from which ixazomib is completely removed by the kidney in a given amount of time, calculated as the amount of ixazomib excreted in the urine divided by the area under the plasma ixazomib concentration-time curve. (NCT01953783)
Timeframe: Day 1 pre-dose and at multiple timepoints (up to Day 14) post-dose
| Intervention | liter per hour (L/hr) (Geometric Mean) |
|---|---|
| Ixazomib | 0.1191 |
Time to reach the maximum observed plasma concentration (Cmax) for TRA, equal to time (hours) to Cmax for TRA after administration, obtained directly from the plasma TRA concentration-time curve. (NCT01953783)
Timeframe: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
| Intervention | hr (Median) |
|---|---|
| Ixazomib | 0.5000 |
Time to reach the maximum observed plasma concentration (Cmax), equal to time (hours) to Cmax of ixazomib after administration, obtained directly from the plasma concentration-time curve. (NCT01953783)
Timeframe: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 14) post-dose
| Intervention | hour (hr) (Median) |
|---|---|
| Ixazomib | 0.5000 |
Time to reach the maximum observed whole blood concentration (Cmax) for TRA, equal to time (hours) to Cmax for TRA after administration, obtained directly from the whole blood TRA concentration-time curve. (NCT01953783)
Timeframe: Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
| Intervention | hr (Median) |
|---|---|
| Ixazomib | 0.6000 |
"The 35-day post-dose data is extrapolated from the average of four participant data from 0-168-hr pooled feces. The data is therefore reported as percentage of dose with measure type as number and measure dispersion as NA." (NCT01953783)
Timeframe: Day 1 pre-dose and at multiple time points (up to Day 35) post-dose
| Intervention | percentage of dose (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| FH6, ixazomib | FH1 | FH2 | FH3, ML00701258 | FH4, ML00701201 | FH5 | FH7, ML00752034 | FH8 | FH9 | |
| Ixazomib | 13.8 | 0.900 | 0.111 | 0.620 | 0.901 | 1.14 | 1.58 | 0.502 | 0.112 |
"The 35-day post-dose data is extrapolated from the average of four participant data from 0-168-hr pooled urine. The data is therefore reported as percentage of dose with measure type as number and measure dispersion as NA." (NCT01953783)
Timeframe: Day 1 pre-dose and at multiple time points (up to Day 35) post-dose
| Intervention | percentage of dose (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U9, ixazomib | U1 | U2 | U3 | U4 | U5, ML00701258 | U6, ML00701201 | U7 | U8 | U10, ML00751996 | U11, ML00749506 | U12, ML00752034 | U13 | |
| Ixazomib | 1.30 | 0.391 | 0.926 | 1.61 | 1.33 | 2.72 | 30.2 | 2.75 | 0.695 | 5.93 | 1.28 | 0.069 | 0.974 |
"The plasma samples were pooled for participants over 816 hrs post-dose, and data was analysed using the Hamilton method time-proportional pooling, and therefore the data is reported as percent of total radioactivity in plasma with measure type as number and measure dispersion as Not applicable, NA." (NCT01953783)
Timeframe: Day 1 pre-dose and at multiple time points (up to 816 hrs) post-dose
| Intervention | percent of total radioactivity in plasma (Number) | ||||
|---|---|---|---|---|---|
| P4, ixazomib | P2, ML00701258 | P3, ML00701201 | P6, ML00749506 | P7, ML00752034 | |
| Ixazomib | 54.2 | 7.91 | 18.9 | 10.6 | 3.20 |
(NCT01953783)
Timeframe: Baseline up to Cycle 5 Day 45
| Intervention | participants (Number) | |
|---|---|---|
| TEAEs | SAEs | |
| Ixazomib | 7 | 1 |
(NCT01953783)
Timeframe: Baseline up to Cycle 5 Day 45
| Intervention | participants (Number) | ||
|---|---|---|---|
| Blood bilirubin increased | Platelet count decreased | Lymphocyte count decreased | |
| Ixazomib | 1 | 1 | 1 |
The number of adverse events and their severity rating will be classified according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, version 3.0. (NCT00856791)
Timeframe: 6 months
| Intervention | Adverse event (Number) |
|---|---|
| ON 01910.Na | 9 |
Progression-free survival, defined as the number of days from the first day of study drug dosing to the day of documented disease progression or death, as assessed using RECIST (Response Evaluation Criteria in Solid Tumors) guidelines according to Therasse P, Arbuck SF, Eisenhauer EA, et al. (2000) J Natl Cancer Inst. 92:205-216. Progressive disease is defined as at least a 20% increase in the sum of the longest diameter (LD)of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00856791)
Timeframe: 6 months
| Intervention | day (Number) |
|---|---|
| ON 01910.Na | 54 |
41 reviews available for glycine and Neoplasms
| Article | Year |
|---|---|
Glycinergic Signaling in Macrophages and Its Application in Macrophage-Associated Diseases.
Topics: Animals; Colitis; Glycine; Humans; Macrophages; Metabolic Diseases; MicroRNAs; Neoplasms; Reperfusio | 2021 |
Phosphatases of regenerating liver are key regulators of metabolism in cancer cells - role of Serine/Glycine metabolism.
Topics: Glycine; Humans; Liver; Neoplasms; Protein Tyrosine Phosphatases; Serine | 2022 |
Pleiotropic Outcomes of Glyphosate Exposure: From Organ Damage to Effects on Inflammation, Cancer, Reproduction and Development.
Topics: DNA Damage; Europe; Gene Expression Regulation; Glycine; Glyphosate; Herbicides; Humans; Inflammatio | 2021 |
Clinical development of IDH1 inhibitors for cancer therapy.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Clinical Trials as Topic; Enzyme Inhibitor | 2022 |
Current status of cancer starvation therapy.
Topics: Amino Acids; Angiogenesis Inhibitors; Glycine; Humans; Integrins; Neoplasms; Serine | 2022 |
Integrin Alpha v Beta 6 (αvβ6) and Its Implications in Cancer Treatment.
Topics: Antigens, Neoplasm; Arginine; Aspartic Acid; Glycine; Humans; Integrin alphaV; Integrins; Neoplasms; | 2022 |
Target enzymes in serine-glycine-one-carbon metabolic pathway for cancer therapy.
Topics: Carbon; Carcinogenesis; Glycine; Humans; Metabolic Networks and Pathways; Neoplasms; Serine | 2023 |
New opportunities for RGD-engineered metal nanoparticles in cancer.
Topics: Amino Acid Sequence; Glycine; Humans; Metal Nanoparticles; Neoplasms; Oligopeptides | 2023 |
The complexity of the serine glycine one-carbon pathway in cancer.
Topics: Animals; Carbon; Glycine; Humans; Metabolic Networks and Pathways; Neoplasms; Serine | 2020 |
Accounting for Multiple Comparisons in Statistical Analysis of the Extensive Bioassay Data on Glyphosate.
Topics: Animals; Animals, Laboratory; Biological Assay; Carcinogenicity Tests; Data Interpretation, Statisti | 2020 |
Reprogramming of serine, glycine and one-carbon metabolism in cancer.
Topics: Animals; Carbon; Cellular Reprogramming; Glycine; Humans; Metabolic Networks and Pathways; Methionin | 2020 |
N-Myristoyltransferase as a Glycine and Lysine Myristoyltransferase in Cancer, Immunity, and Infections.
Topics: Acyltransferases; Animals; Communicable Diseases; Enzyme Inhibitors; Glycine; Humans; Immunity, Inna | 2020 |
Environmental Pollution, Oxidative Stress and Thioretinaco Ozonide: Effects of Glyphosate, Fluoride and Electromagnetic Fields on Mitochondrial Dysfunction in Carcinogenesis, Atherogenesis and Aging.
Topics: Aging; Animals; Atherosclerosis; Carcinogenesis; Electromagnetic Fields; Environmental Pollution; Fl | 2020 |
Cancer Cell Metabolites: Updates on Current Tracing Methods.
Topics: Amino Acids; Citric Acid; Glucose; Glycine; Humans; Isotope Labeling; Lactic Acid; Neoplasms; Succin | 2020 |
The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer.
Topics: Acetylation; Boron Compounds; Bortezomib; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis | 2021 |
Serine, glycine and one‑carbon metabolism in cancer (Review).
Topics: Animals; Antineoplastic Agents; Carbon; Carcinogenesis; Disease Models, Animal; Glycine; Humans; Met | 2021 |
The ins and outs of serine and glycine metabolism in cancer.
Topics: Animals; Glycine; Humans; Neoplasms; Serine | 2021 |
Next-generation proteasome inhibitors for cancer therapy.
Topics: Antineoplastic Agents; Boron Compounds; Bortezomib; Drug Resistance, Neoplasm; Glycine; Humans; Neop | 2018 |
Glyphosate-based herbicides and cancer risk: a post-IARC decision review of potential mechanisms, policy and avenues of research.
Topics: Animals; Carcinogens; Environmental Exposure; Glycine; Glyphosate; Herbicides; Humans; Microbiota; M | 2018 |
Clinical and marketed proteasome inhibitors for cancer treatment.
Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Lactones; Neoplasms; Oligopeptides; Pro | 2013 |
Serine, glycine and one-carbon units: cancer metabolism in full circle.
Topics: Epigenesis, Genetic; Glycine; Humans; Methylation; Neoplasms; Oxidation-Reduction; Serine | 2013 |
Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.
Topics: Antineoplastic Agents; Biomarkers; Glycine; Humans; Myelodysplastic Syndromes; Nanotechnology; Neopl | 2013 |
[Glyphosate and its formulations--toxicity, occupational and environmental exposure].
Topics: Agriculture; Animals; Cholinesterase Inhibitors; Environmental Exposure; Glycine; Glyphosate; Herbic | 2013 |
Serine and glycine metabolism in cancer.
Topics: Cell Proliferation; Glycine; Humans; Metabolic Networks and Pathways; Neoplasms; Serine | 2014 |
[Proteasome inhibitor].
Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Molecular Targeted Therapy; Neoplasms; | 2014 |
Systematic review and meta-analysis of glyphosate exposure and risk of lymphohematopoietic cancers.
Topics: Glycine; Glyphosate; Herbicides; Hodgkin Disease; Humans; Leukemia; Multiple Myeloma; Neoplasms; Ris | 2016 |
Give it or take it: the flux of one-carbon in cancer cells.
Topics: Animals; Carbon; Carbon Cycle; Cell Compartmentation; Cytosol; Embryonic Development; Glycine; Human | 2016 |
Beneficial Effects of the Amino Acid Glycine.
Topics: Animals; Antioxidants; Diabetes Mellitus, Type 2; Glycine; Humans; Insulin Resistance; Kidney; Liver | 2017 |
IGFBP3 polymorphisms and risk of cancer: a meta-analysis.
Topics: Alanine; Alleles; Amino Acid Substitution; Case-Control Studies; Confidence Intervals; Genetic Predi | 2010 |
Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
Topics: Aniline Compounds; Animals; Cell Cycle Proteins; Clinical Trials as Topic; Cyclic N-Oxides; Drug Eva | 2009 |
Aminopeptidase N (CD13) as a target for cancer chemotherapy.
Topics: CD13 Antigens; Cell Proliferation; Clinical Trials as Topic; Glycine; Humans; Hydroxamic Acids; Leuc | 2011 |
Epidemiologic studies of glyphosate and cancer: a review.
Topics: Case-Control Studies; Cohort Studies; Glycine; Glyphosate; Herbicides; Humans; Neoplasms | 2012 |
[Thrombosis in spite of warfarin--what should be done?].
Topics: Anticoagulants; Antiphospholipid Syndrome; Azetidines; Benzylamines; Blood Coagulation; Glycine; Hep | 2001 |
Glycine--an inert amino acid comes alive.
Topics: Adjuvants, Immunologic; Amino Acids; Cytoprotection; Fibrinolytic Agents; Glycine; Humans; Neoplasms | 2003 |
[Glutathione: its biosynthesis, induction agents and concentrations in selected diseases].
Topics: Animals; Cysteine; Cystine; Glutamic Acid; Glutathione; Glycine; Humans; Male; Neoplasms | 2004 |
New compounds for neutron capture therapy (NCT) and their significance.
Topics: Animals; Borohydrides; Boron Compounds; Combined Modality Therapy; Cricetinae; Deoxyuridine; Glycine | 1984 |
[Synthetic immunostimulation and its use in antineoplasm therapy].
Topics: Adjuvants, Immunologic; Amino Acids; Anti-Bacterial Agents; Aziridines; Glycine; Hormones; Humans; I | 1982 |
Acivicin. An antitumor antibiotic.
Topics: Animals; Antibiotics, Antineoplastic; Glycine; Humans; Isoxazoles; Neoplasms; Neoplasms, Experimenta | 1981 |
Anticoagulation: the present and future.
Topics: Administration, Oral; Amino Acid Chloromethyl Ketones; Anticoagulants; Arginine; Azetidines; Benzyla | 2001 |
Oncogenous rickets: possible elaboration by a tumor of a humoral substance inhibiting tubular reabsorption of phosphate.
Topics: Calcitonin; Calcium; Child; Glycine; Growth Disorders; Humans; Kidney Tubules; Kidney Tubules, Proxi | 1973 |
[Action of the adrenal cortex hormones on lymphiod tissue].
Topics: Adrenal Cortex Hormones; Amino Acids; Animals; Carbon Isotopes; Cell Membrane; Enzyme Induction; Glu | 1967 |
19 trials available for glycine and Neoplasms
| Article | Year |
|---|---|
A phase i study of ixazomib and erlotinib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2022 |
Open-label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non-myeloid malignancies.
Topics: Anemia; Antineoplastic Agents; Erythropoietin; Glycine; Hematinics; Hemoglobins; Humans; Isoquinolin | 2023 |
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.
Topics: Adult; Aged; Angiogenesis Inhibitors; Boron Compounds; Glycine; Humans; Indazoles; Kaplan-Meier Esti | 2020 |
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Ana
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boron Compounds; Clarit | 2018 |
A phase I study to assess the mass balance, excretion, and pharmacokinetics of [
Topics: Administration, Oral; Aged; Boron Compounds; Carbon Radioisotopes; Feces; Female; Glycine; Humans; M | 2018 |
Biotransformation of [
Topics: Administration, Oral; Antineoplastic Agents; Area Under Curve; Biotransformation; Boron Compounds; C | 2018 |
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relations | 2020 |
Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Cell Cycle Proteins; Enzyme Inhibitors; Fe | 2014 |
Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Benzamides; Bio | 2014 |
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
Topics: Activating Transcription Factor 3; Adult; Aged; Boron Compounds; Cohort Studies; Dose-Response Relat | 2015 |
The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
Topics: Aged; Aged, 80 and over; Area Under Curve; Biological Availability; Boron Compounds; Cross-Over Stud | 2016 |
Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Boron Compounds; Female; Glycine; Humans; Live | 2016 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Dose-Response Relationship, Drug; F | 2008 |
A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Aminopeptidases; Dose-Response Relationship, Drug; Enzyme Inhibitors | 2009 |
A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Aminopeptidases; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sc | 2010 |
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.
Topics: Adult; Aged; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gly | 2011 |
Pharmaceutical development of the novel arsenical based cancer therapeutic GSAO for Phase I clinical trial.
Topics: Angiogenesis Inhibitors; Antioxidants; Arsenicals; Calorimetry, Differential Scanning; Chemistry, Ph | 2012 |
Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Ce | 2012 |
[First results of the clinical use of injectable lysine acetylsalicylate].
Topics: Adult; Aged; Analgesics; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Drug Combinations | 1972 |
173 other studies available for glycine and Neoplasms
| Article | Year |
|---|---|
Glutamine Antagonist GA-607 Causes a Dramatic Accumulation of FGAR which can be used to Monitor Target Engagement.
Topics: Animals; Biomarkers, Pharmacological; Biomarkers, Tumor; Chromatography, Liquid; Drug Development; G | 2021 |
The impact of physiological metabolite levels on serine uptake, synthesis and utilization in cancer cells.
Topics: Biosynthetic Pathways; Cell Line, Tumor; Cell Proliferation; Culture Media; Glycine; Humans; Hypoxan | 2021 |
Platinum-based nanocomposites loaded with MTH1 inhibitor amplify oxidative damage for cancer therapy.
Topics: Arginine; Aspartic Acid; Catalase; Cell Line, Tumor; Glycine; Humans; Hydrogen Peroxide; Liposomes; | 2022 |
Exploratory Metabolomics Underscores the Folate Enzyme ALDH1L1 as a Regulator of Glycine and Methylation Reactions.
Topics: Aldehyde Dehydrogenase 1 Family; Folic Acid; Glycine; Humans; Metabolomics; Methylation; Neoplasms; | 2022 |
Exploratory Metabolomics Underscores the Folate Enzyme ALDH1L1 as a Regulator of Glycine and Methylation Reactions.
Topics: Aldehyde Dehydrogenase 1 Family; Folic Acid; Glycine; Humans; Metabolomics; Methylation; Neoplasms; | 2022 |
Exploratory Metabolomics Underscores the Folate Enzyme ALDH1L1 as a Regulator of Glycine and Methylation Reactions.
Topics: Aldehyde Dehydrogenase 1 Family; Folic Acid; Glycine; Humans; Metabolomics; Methylation; Neoplasms; | 2022 |
Exploratory Metabolomics Underscores the Folate Enzyme ALDH1L1 as a Regulator of Glycine and Methylation Reactions.
Topics: Aldehyde Dehydrogenase 1 Family; Folic Acid; Glycine; Humans; Metabolomics; Methylation; Neoplasms; | 2022 |
Identification and Biological Evaluation of a Water-Soluble Fullerene Nanomaterial as BTK Kinase Inhibitor.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Caspases; Fullerenes; Glycine; Hematolog | 2023 |
Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRAS
Topics: Animals; Antineoplastic Agents; Drug Design; Glycine; Humans; Lung Neoplasms; Mutation; Neoplasms; P | 2023 |
Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation.
Topics: Animals; Cell Line, Tumor; Cellular Reprogramming; Energy Metabolism; Glycine; Humans; Mice; Mutatio | 2019 |
Nutraceutical targeting of TLR4 signaling has potential for prevention of cancer cachexia.
Topics: 3-Hydroxybutyric Acid; Adipocytes; Biotin; Cachexia; Carnitine; Catechin; Coumaric Acids; Dietary Su | 2019 |
Enlargement of a Modular System-Synthesis and Characterization of an
Topics: Boron; Boron Compounds; Boron Neutron Capture Therapy; Carboxylic Acids; Drug Delivery Systems; Este | 2019 |
Difficulties in establishing a causal link between chemical exposures and cancer cannot be overcome by court assessments.
Topics: Environmental Exposure; Environmental Pollutants; Glycine; Glyphosate; Humans; Jurisprudence; Neopla | 2020 |
Acetonitrilated Unsymmetric BODIPYs having glycine fluorescence responsive quenching: Design, synthesis and spectroscopic properties.
Topics: Antineoplastic Agents; Boron Compounds; Cell Line, Tumor; Fluorescent Dyes; Glycine; Humans; Microsc | 2020 |
Glyphosate and cancer: the importance of the whole picture.
Topics: Agrochemicals; Glycine; Glyphosate; Humans; Neoplasms; Pest Control | 2020 |
Questioning Existing Cancer Hazard Evaluation Standards in the Name of Statistics.
Topics: Biological Assay; Glycine; Glyphosate; Humans; Neoplasms; Reference Standards | 2020 |
Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent.
Topics: Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Crystallography, X-Ray; Drug Contaminati | 2020 |
Serine restriction alters sphingolipid diversity to constrain tumour growth.
Topics: Alanine; Animals; Cell Adhesion; Cell Division; Diet; Female; Glycine; HCT116 Cells; Humans; Membran | 2020 |
Germline HOXB13 G84E mutation carriers and risk to twenty common types of cancer: results from the UK Biobank.
Topics: Adult; Aged; Amino Acid Substitution; Biological Specimen Banks; Case-Control Studies; Female; Gene | 2020 |
Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy.
Topics: Activating Transcription Factor 4; Animals; Cell Line, Tumor; Cell Proliferation; Female; Glycine; H | 2021 |
Low immunogenicity of common cancer hot spot mutations resulting in false immunogenic selection signals.
Topics: Alleles; Carcinogenesis; Cell Line, Tumor; Gene Frequency; Genotype; Glycine; HLA Antigens; Humans; | 2021 |
Topics: Adult; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Animals; Anti-Bacterial Agents; Anti- | 2021 |
Targeting of carbonic anhydrase IX-positive cancer cells by glycine-coated superparamagnetic nanoparticles.
Topics: Carbonic Anhydrase IX; Glycine; Humans; Magnetic Iron Oxide Nanoparticles; Nanoparticles; Neoplasms | 2021 |
Effect of lipophilicity of amylamine and amylglycine ligands on biological activity of new anticancer cisplatin analog.
Topics: Amines; Antineoplastic Agents; Circular Dichroism; Cisplatin; DNA; Glycine; HCT116 Cells; Humans; Li | 2018 |
When cancer needs what's non-essential.
Topics: Animals; Cell Proliferation; Diet, Protein-Restricted; Energy Metabolism; Glycine; Humans; Mice; Neo | 2017 |
Several inhibitors of the Plk1 Polo-Box Domain turn out to be non-specific protein alkylators.
Topics: Alkylation; Antineoplastic Agents; Benzoates; Benzoquinones; Cell Cycle Proteins; Glycine; Humans; M | 2017 |
Exploiting tumour addiction with a serine and glycine-free diet.
Topics: Diet; Glycine; Humans; Neoplasms; Serine | 2017 |
Short stretches of rare codons regulate translation of the transcription factor ZEB2 in cancer cells.
Topics: Amino Acid Motifs; Cell Line, Tumor; Codon; Epithelial-Mesenchymal Transition; Glycine; Humans; Leuc | 2017 |
Glyphosate Use and Cancer Incidence in the Agricultural Health Study.
Topics: Adult; Aged; Aged, 80 and over; Agricultural Workers' Diseases; Agriculture; Cohort Studies; Farmers | 2018 |
Glyphosate Use and Cancer Incidence in the Agricultural Health Study: An Epidemiologic Perspective.
Topics: Agriculture; Glycine; Glyphosate; Humans; Incidence; Neoplasms | 2018 |
Commentary: IARC Monographs Program and public health under siege by corporate interests.
Topics: Carcinogens; Conflict of Interest; Glycine; Glyphosate; Herbicides; Humans; International Agencies; | 2018 |
Ready reckoning.
Topics: California; Chemical Industry; Glycine; Glyphosate; Herbicides; Humans; Liability, Legal; Neoplasms | 2018 |
Analysis of glucose-derived amino acids involved in one-carbon and cancer metabolism by stable-isotope tracing gas chromatography mass spectrometry.
Topics: Amino Acids; Carbon; Carbon Isotopes; Cell Line, Tumor; Gas Chromatography-Mass Spectrometry; Glucos | 2019 |
Amphiphilic Glycopolypeptide Star Copolymer-Based Cross-Linked Nanocarriers for Targeted and Dual-Stimuli-Responsive Drug Delivery.
Topics: Alkynes; Antibiotics, Antineoplastic; Cross-Linking Reagents; Delayed-Action Preparations; Doxorubic | 2019 |
Re: Glyphosate Use and Cancer Incidence in the Agricultural Health Study.
Topics: Agriculture; Glycine; Glyphosate; Humans; Incidence; Neoplasms | 2019 |
Response to Sheppard and Shaffer.
Topics: Glycine; Glyphosate; Humans; Incidence; Neoplasms | 2019 |
Blood Circulation-Prolonging Peptides for Engineered Nanoparticles Identified via Phage Display.
Topics: Amino Acid Sequence; Arginine; Aspartic Acid; Bacteriophage M13; Biological Transport; Cell Surface | 2019 |
A Highly Effective π-π Stacking Strategy To Modify Black Phosphorus with Aromatic Molecules for Cancer Theranostics.
Topics: Arginine; Aspartic Acid; Glycine; Humans; Nanocomposites; Neoplasms; Peptides; Phosphorus; Photother | 2019 |
Design of an Amphiphilic Poly(aspartamide)-mediated Self-assembled Nanoconstruct for Long-Term Tumor Targeting and Bioimaging.
Topics: Amines; Animals; Cell Line, Tumor; Doxorubicin; Gene Expression Regulation, Neoplastic; Glycine; Hum | 2019 |
Expert Review Under Attack: Glyphosate, Talc, and Cancer.
Topics: Asbestos; Glycine; Glyphosate; Humans; Neoplasms; Politics; Talc | 2019 |
Fighting Independent Risk Assessment of Talc and Glyphosate: Whose Benefit Is It Anyway?
Topics: Glycine; Glyphosate; Humans; Neoplasms; Risk Assessment; Talc | 2019 |
Plurality of opinion, scientific discourse and pseudoscience: an in depth analysis of the Séralini et al. study claiming that Roundup™ Ready corn or the herbicide Roundup™ cause cancer in rats.
Topics: Animals; Cultural Diversity; Drug Tolerance; Food, Genetically Modified; Glycine; Glyphosate; Herbic | 2013 |
A novel manganese complex, Mn-(II) N-(2-hydroxy acetophenone) glycinate overcomes multidrug-resistance in cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Line, Tumor; Cell Survival; Cells | 2013 |
Synthesis, characterization and equilibrium studies of some potential antimicrobial and antitumor complexes of Cu(II), Ni(II), Zn(II) and Cd(II) ions involving 2-aminomethylbenzimidazole and glycine.
Topics: Anti-Infective Agents; Antineoplastic Agents; Bacteria; Bacterial Infections; Benzimidazoles; Cell L | 2013 |
Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia.
Topics: Adipose Tissue; Animals; Body Mass Index; Cachexia; Cell Line, Tumor; Disease Models, Animal; Fatty | 2014 |
Glyphosate and AMPA inhibit cancer cell growth through inhibiting intracellular glycine synthesis.
Topics: Apoptosis; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Epithelial | 2013 |
Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells.
Topics: Adenosine Triphosphate; Amino Acid Oxidoreductases; Animals; Carrier Proteins; Cell Line, Tumor; Emb | 2013 |
Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells.
Topics: Carbon; Cell Growth Processes; Glycine; HCT116 Cells; Humans; MCF-7 Cells; Metabolic Networks and Pa | 2014 |
LRRK2-G2019S mutation is not associated with an increased cancer risk: a kin-cohort study.
Topics: Case-Control Studies; Cohort Studies; Female; Glycine; Humans; Leucine-Rich Repeat Serine-Threonine | 2014 |
Synthesis and characterization of a glycine-modified heptamethine indocyanine dye for in vivo cancer-targeted near-infrared imaging.
Topics: Animals; Biocompatible Materials; Dose-Response Relationship, Drug; Fluorescent Dyes; Glycine; Hep G | 2014 |
In vitro antitumor mechanism of (E)-N-(2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyridin-3-yl)methanesulfonamide.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, | 2015 |
Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.
Topics: Aged; Aged, 80 and over; Europe; Female; Genetic Association Studies; Genetic Predisposition to Dise | 2015 |
Bioinformatics analysis of the serine and glycine pathway in cancer cells.
Topics: Animals; Computational Biology; Genomics; Glycine; Humans; Mice; Neoplasms; Serine; Survival Analysi | 2014 |
Characterization of the usage of the serine metabolic network in human cancer.
Topics: Carbon; Gene Expression Regulation, Neoplastic; Glutathione; Glycine; Humans; Metabolic Flux Analysi | 2014 |
Synthesis and properties of novel water-soluble fullerene-glycine derivatives as new materials for cancer therapy.
Topics: Biocompatible Materials; Carbon; Cell Line, Tumor; Drug Design; Flow Cytometry; Fullerenes; Glycine; | 2015 |
Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.
Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials | 2015 |
Carcinogenicity of tetrachlorvinphos, parathion, malathion, diazinon, and glyphosate.
Topics: Carcinogenesis; Diazinon; Glycine; Glyphosate; Humans; Malathion; Neoplasms; Parathion; Pesticides; | 2015 |
Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.
Topics: Animals; Boron Compounds; Clinical Trials, Phase I as Topic; Dogs; Electrocardiography; Ether-A-Go-G | 2015 |
Studies on human eRF3-PABP interaction reveal the influence of eRF3a N-terminal glycin repeat on eRF3-PABP binding affinity and the lower affinity of eRF3a 12-GGC allele involved in cancer susceptibility.
Topics: Alleles; Binding Sites; Genetic Predisposition to Disease; Genetic Variation; Glycine; Humans; Model | 2016 |
Differences in the carcinogenic evaluation of glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (EFSA).
Topics: Carcinogens; Consumer Product Safety; European Union; Food Safety; Glycine; Glyphosate; Herbicides; | 2016 |
[Is there a threat to ban the herbicide glyphosate?].
Topics: Consumer Product Safety; Food Contamination; Germany; Glycine; Glyphosate; Hazard Analysis and Criti | 2016 |
On the International Agency for Research on Cancer classification of glyphosate as a probable human carcinogen.
Topics: Animals; Carcinogenicity Tests; Carcinogens; Glycine; Glyphosate; Humans; International Agencies; Mo | 2018 |
Quantitative Method to Investigate the Balance between Metabolism and Proteome Biomass: Starting from Glycine.
Topics: Amino Acids; Cell Line, Tumor; Cell Proliferation; Glycine; Humans; Metabolic Networks and Pathways; | 2016 |
IARC use of oxidative stress as key mode of action characteristic for facilitating cancer classification: Glyphosate case example illustrating a lack of robustness in interpretative implementation.
Topics: Animals; Carcinogens; Glycine; Glyphosate; Humans; International Agencies; Neoplasms; Oxidative Stre | 2017 |
(68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging.
Topics: Animals; Cell Line, Tumor; Dimerization; Female; Gallium Radioisotopes; Glycine; Humans; Integrin al | 2009 |
Incorporation of 5-chlorocytosine into mammalian DNA results in heritable gene silencing and altered cytosine methylation patterns.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Cytosine; DNA; DNA Damage; DNA Replication; Gene Silenci | 2009 |
A point mutation (G574A) in the chemokine receptor CXCR4 detected in human cancer cells enhances migration.
Topics: Alanine; Amino Acid Sequence; Amino Acid Substitution; Animals; Cell Line, Tumor; Cell Movement; Cel | 2009 |
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
Topics: Animals; Boron Compounds; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Drug Screening | 2010 |
Inhibition of epidermal growth factor receptor-overexpressing cancer cells by camptothecin, 20-(N,N-diethyl) glycinate.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Evaluation, Preclinical; Erb | 2010 |
[Effect of delta-sleep inducing peptide preparation Deltaran on longevity, physiological functions, and carcinogenesis in mice].
Topics: Animals; Antioxidants; Biomarkers; Body Weight; Delta Sleep-Inducing Peptide; Drug Administration Sc | 2009 |
Synthesis and evaluation of a bifunctional chelate for development of Bi(III)-labeled radioimmunoconjugates.
Topics: Antibodies, Monoclonal, Humanized; Bismuth; Drug Evaluation, Preclinical; Drug Stability; Glycine; H | 2011 |
Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis.
Topics: Amino Acid Sequence; Antigens, CD; Carcinoma, Non-Small-Cell Lung; Cell Adhesion Molecules, Neuronal | 2012 |
Next-generation proteasome blockers promise safer cancer therapy.
Topics: Antineoplastic Agents; Boron Compounds; Clinical Trials as Topic; Cysteine Proteinase Inhibitors; Dr | 2012 |
Reprogramming of TAM toward proimmunogenic type through regulation of MAP kinases using a redox-active copper chelate.
Topics: Animals; Cell Line, Tumor; Chelating Agents; Enzyme Activation; Female; Glycine; Interferon-gamma; I | 2012 |
Injectable poly(organophosphazene)-camptothecin conjugate hydrogels: synthesis, characterization, and antitumor activities.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Stability; D | 2012 |
Cancer. Systems biology, metabolomics, and cancer metabolism.
Topics: Cell Proliferation; Glycine; Humans; Neoplasms | 2012 |
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Topics: Breast Neoplasms; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Transformation, | 2012 |
Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001.
Topics: Amides; Animals; Aurora Kinase A; Aurora Kinases; Benzimidazoles; Cell Cycle Proteins; Cell Division | 2012 |
Overexpression of the mitochondrial folate and glycine-serine pathway: a new determinant of methotrexate selectivity in tumors.
Topics: Biological Transport; Folic Acid; Folic Acid Antagonists; Glycine; Humans; Methotrexate; Mitochondri | 2013 |
A wholly nutritional 'multifocal angiostatic therapy' for control of disseminated cancer.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Copper; Cyclic AMP; Diet; Diet, Vege | 2003 |
Oncogenic mutations and packing defects in protein structure.
Topics: Alanine; Amino Acid Sequence; Amino Acid Substitution; Arginine; Binding Sites; Glycine; Hydrogen Bo | 2003 |
In vitro incorporation of glycine-2-C14 into purines and proteins.
Topics: Glycine; In Vitro Techniques; Neoplasms; Nucleic Acids; Proteins; Purines | 1953 |
Intracellular distribution of radioactivity in nucleic acid nucleotides and proteins following simultaneous administration of P32 and glycine-2-C14.
Topics: Cytoplasm; Glycine; Neoplasms; Nucleic Acids; Nucleotides; Phosphorus; Phosphorus Radioisotopes; Pro | 1953 |
Studies on the effect of X-rays on the biochemistry and cellular composition of ascites tumors. II. Changes in the pattern of glycine-2-14C incorporation during the first two hours after irradiation in vivo.
Topics: Animals; Ascites; Carcinoma, Ehrlich Tumor; Glycine; Neoplasms; X-Rays | 1954 |
Kinetic studies on the influx of glycine-1-C14 into the Ehrlich mouse ascites carcinoma cell.
Topics: Animals; Ascites; Fabaceae; Glycine; Kinetics; Mice; Neoplasms | 1954 |
Glycine and adenine as precursors of nucleic acid purines in tumor-bearing mice.
Topics: Adenine; Animals; Glycine; Mice; Neoplasms; Nucleic Acids; Purines | 1955 |
The biosynthesis of free glycine and serine by tumors.
Topics: Glycine; Humans; Neoplasms; Serine | 1955 |
Glycerol metabolism of normal and malignant lymphatic tissue; the preferential labeling of tumor serine and glycine.
Topics: Glycerol; Glycine; Humans; Lymphatic System; Lymphoid Tissue; Lymphoma; Lymphoma, Non-Hodgkin; Neopl | 1956 |
Glycerol metabolism of normal and malignant lymphatic tissue; the preferential labeling of tumor serine and glycine.
Topics: Glycerol; Glycine; Humans; Lymphatic System; Lymphoid Tissue; Lymphoma; Lymphoma, Non-Hodgkin; Neopl | 1956 |
Glycerol metabolism of normal and malignant lymphatic tissue; the preferential labeling of tumor serine and glycine.
Topics: Glycerol; Glycine; Humans; Lymphatic System; Lymphoid Tissue; Lymphoma; Lymphoma, Non-Hodgkin; Neopl | 1956 |
Glycerol metabolism of normal and malignant lymphatic tissue; the preferential labeling of tumor serine and glycine.
Topics: Glycerol; Glycine; Humans; Lymphatic System; Lymphoid Tissue; Lymphoma; Lymphoma, Non-Hodgkin; Neopl | 1956 |
[Effect of glycine on liver glycogen content in normal and tumor-bearing mice following administration of medinal].
Topics: Animals; Barbital; Barbiturates; Glycine; Glycine Agents; Glycogen; Glycogenolysis; Liver; Liver Gly | 1956 |
The exchangeability of glycine accumulated by carcinoma cells.
Topics: Fabaceae; Glycine; Neoplasms | 1957 |
In vitro studies with antisera against tumor cell protein fractions.
Topics: Glycine; Immune Sera; In Vitro Techniques; Neoplasm Proteins; Neoplasms; Proteins | 1957 |
Concentration work and energy dissipation in active transport of glycine into carcinoma cells.
Topics: Biological Transport, Active; Fabaceae; Glycine; Neoplasms | 1957 |
Purine metabolism in mouse ascites tumor cells. 1. Effect of performed purines on in vitro incorporation of glycine-2-C14.
Topics: Animals; Ascites; Carcinoma, Ehrlich Tumor; Glycine; In Vitro Techniques; Metabolic Networks and Pat | 1958 |
Effects of various steroids and metabolic inhibitors on the incorporation of glycine-2-C 14 into total proteins and nucleic acids of normal and malignant lymphocytes in vitro.
Topics: Encephalomyelitis; Glycine; Humans; In Vitro Techniques; Lymphocytes; Metabolism; Neoplasms; Nucleic | 1958 |
Effect of cancer and fasting on oxidation of labeled acetate, glucose and glycine to C1402.
Topics: Acetates; Carbohydrate Metabolism; Carbon Dioxide; Fasting; Glucose; Glycine; Neoplasms; Oxidation-R | 1959 |
Protein turnover in glycine-C14-labelled Landschütz Ascites tumor cells.
Topics: Animals; Ascites; Carcinoma, Ehrlich Tumor; Glycine; Neoplasms; Proteins; Proteolysis | 1959 |
In vitro uptake of 14C labelled glycine by the cells of pleural and peritoneal fluid.
Topics: Ascitic Fluid; Glycine; In Vitro Techniques; Neoplasms; Peritoneum; Pleura | 1959 |
The effects of alkylating agents on the incorporation of glycine-1-C14 into tissue proteins in vitro.
Topics: Alkylating Agents; Antineoplastic Agents; Glycine; In Vitro Techniques; Neoplasms; Proteins | 1960 |
[Relation between cholinesterase activity and incorporation of amino acids into proteins. II. Incorporation of C14-labeled glycine into homogenized tissue of tumor homo- and heterografts under the influence of acetylphosphate].
Topics: Acetylcholine; Amino Acids; Animals; Biochemical Phenomena; Cholinesterases; Glycine; Heterografts; | 1960 |
The effect of glycine transport on potassium fluxes in the Ehrlich mouse ascites tumor cell.
Topics: Animals; Ascites; Carcinoma, Ehrlich Tumor; Glycine; Ion Transport; Mice; Neoplasms; Potassium | 1961 |
The effects of uncoupling agents on the uptake and incorporation of glycine by transplantable tumors.
Topics: Antimetabolites; Glycine; Neoplasm Transplantation; Neoplasms; Uncoupling Agents | 1961 |
Isolated cells: normal and tumor. III. Effects of bathing media upon intracellular uptake of glycine and upon protein synthesis.
Topics: Cytoplasm; Glycine; Neoplasms; Protein Biosynthesis; Proteins | 1960 |
Incorporation of Zn-65 in the sub-cellular fractions of the liver and spontaneously occurring mammary tumours of mice after the injection of zinc-glycine containing Zn-65.
Topics: Animals; Glycine; Liver; Mice; Neoplasms; Zinc | 1959 |
[Effect of ribonucleic acid and its hydrolysates on the inclusion of glycine-1-C 14 into proteins of normal and tumor tissues].
Topics: Biochemical Phenomena; Fabaceae; Glycine; Neoplasms; Proteins; RNA | 1959 |
The human tumor-egg host system. II. Discovery and properties of a new antitumor agent, hadacidin.
Topics: Antineoplastic Agents; Glycine; Humans; Neoplasms | 1962 |
[Research on the modification of amino-peptidase in the blood of healthy subjects and tumor patients by D-leucine and D-leucyl-glycyl-glycine].
Topics: Endopeptidases; Glycine; Healthy Volunteers; Humans; Hydrolases; Leucine; Neoplasms; Oligopeptides; | 1961 |
Biochemical studies of the division cycle of mammalian cells: evidence for the premitotic period.
Topics: Animals; Cell Division; DNA; DNA, Neoplasm; Glycine; Humans; Mast Cells; Methotrexate; Neoplasms; Ne | 1963 |
Teratogenic effect of Hadacidin (a new growth inhibitory chemical) on the rat fetus.
Topics: Animals; Antineoplastic Agents; Congenital Abnormalities; Fetus; Glycine; Neoplasms; Rats | 1963 |
[The action of gamma globulin antibodies on the incorporation of glycine-2-C14 into the cells of Walker and Yoshida tumors].
Topics: Animals; Antibodies; Carcinoma; Carcinoma 256, Walker; gamma-Globulins; Glycine; Humans; Neoplasms; | 1962 |
Effects of hadacidin on human tumors grown in eggs and rats.
Topics: Animals; Antineoplastic Agents; Glycine; Neoplasms; Neoplasms, Experimental; Rats | 1962 |
[THE INCORPORATION OF C-14 LABELED GLYCINE INTO ERYTHROCYTIC REDUCED GLUTATHIONE. I. IN PATIENTS WITH MALIGNANT NEOPLASMS].
Topics: Carbon Isotopes; Erythrocytes; Fabaceae; Glutathione; Glycine; Humans; Metabolism; Neoplasms | 1963 |
PEPITASE ACTIVITIES IN TISSUES OF TUMOR-BEARING RATS.
Topics: Animals; Carcinoma 256, Walker; Carcinoma, Hepatocellular; Erythrocytes; Glycine; Leucine; Liver; Li | 1963 |
STUDIES ON AMINO ACID INCORPORATION INTO PROTEIN OF TUMORS INDUCED BY ROUS SARCOMA VIRUS AND HYPERPLASIA INDUCED BY FOWL POX VIRUS IN CHORIOALLANTOIC MEMBRANE OF CHICKEN EMBRYOS.
Topics: Amino Acids; Animals; Avian Sarcoma Viruses; Chick Embryo; Chickens; Chorioallantoic Membrane; Enzym | 1963 |
[CONTRIBUTION TO THE STUDY OF RIBONUCLEOPROTEINS OF NORMAL AND NEOPLASTIC TISSUES].
Topics: Alanine; Arginine; Aspartic Acid; Chemical Phenomena; Chemistry; Glutamates; Glycine; Isoleucine; Le | 1963 |
[ACTION OF METABOLIC INHIBITORS ON ENERGY METABOLISM AND ON PROTEIN SYNTHESIS OF TUMOR AND EMBRYONAL CELLS].
Topics: Adenosine Triphosphate; Amino Acids; Antimetabolites; Carcinoma, Hepatocellular; Cell Biology; Chick | 1963 |
TRANSAMIDINASE ACTIVITIES IN VITRO OF KIDNEYS FROM TUMOR-BEARING MICE AND RATS FED DIETS SUPPLEMENTED WITH PROTEIN OR CERTAIN AMINO ACIDS.
Topics: Amidinotransferases; Amino Acids; Animals; Arginine; Blood Chemical Analysis; Carcinoma 256, Walker; | 1964 |
A TRANSPORT SYSTEM SERVING FOR MONO- AND DIAMINO ACIDS.
Topics: Amino Acids; Aminobutyrates; Aminoisobutyric Acids; Arginine; Asparagine; Carbon Isotopes; Carcinoma | 1964 |
CHROMOSOMAL ABERRATIONS INDUCED BY HYPONITRITE AND HYDROXYLAMINE DERIVATIVES.
Topics: Antineoplastic Agents; Carcinogens; Cell Division; Chromosome Aberrations; Cricetinae; DNA; DNA, Neo | 1964 |
FREE AMINO ACIDS OF HUMAN BREAST CANCER.
Topics: Amino Acids; Asparagine; Aspartic Acid; Breast Neoplasms; Chromatography; Citrulline; Glutamates; Gl | 1964 |
THE HUMAN TUMOR-EGG HOST SYSTEM. III. TUMOR-INHIBITORY PROPERTIES OF TENUAZONIE ACID.
Topics: Adenocarcinoma; Antineoplastic Agents; Aspergillus; Azaserine; Carcinoma, Bronchogenic; Chick Embryo | 1964 |
FURTHER STUDIES ON THE EFFECT OF THIOTEPA ON THE SYNTHESIS OF PROTEIN AND NUCLEIC ACIDS IN TUMOR-BEARING MICE.
Topics: Animals; DNA; DNA, Neoplasm; Glycine; Lymphoma, Non-Hodgkin; Metabolism; Mice; Neoplasm Proteins; Ne | 1964 |
[THE EFFECT OF 2-DESOXYGLUCOSE ON ENERGY METABOLISM AND PROTEIN SYNTHESIS OF TUMOR CELLS AND NORMAL CELLS].
Topics: Animals; Antimetabolites; Bone Marrow; Carcinoma, Hepatocellular; Chick Embryo; Embryo, Mammalian; E | 1964 |
INHIBITION OF DNA SYNTHESIS IN MAMMALIAN CELLS BY ACTIDIONE.
Topics: Adenine; Adenine Nucleotides; Anti-Bacterial Agents; Aspartic Acid; Carbon Isotopes; Carcinoma, Squa | 1964 |
EFFECT OF DIETARY GLYCINE ON TRANSAMIDINASE ACTIVITY OF TUMOR BEARING MICE.
Topics: Amidinotransferases; Animals; Creatine; Creatinine; Diet; Glycine; Humans; Mice; Neoplasms | 1964 |
RADIOAUTOGRAPHIC EVALUATION OF FREEZE-THAW BUFFERS USING NUCLEIC ACID- AND GLYCINE-RELATED SYNTHETIC SYSTEMS IN VITRO.
Topics: Adenine; Autoradiography; Buffers; Dextrans; Dimethyl Sulfoxide; Glycerol; Glycine; In Vitro Techniq | 1964 |
THE EFFECTS OF CORTISOL ON THE INCORPORATION OF GLYCINE CARBON INTO THE NUCLEIC ACIDS OF NORMAL AND MALIGNANT TISSUES.
Topics: Carbon; Carbon Isotopes; Carcinoma, Hepatocellular; DNA; DNA, Neoplasm; Glycine; Hydrocortisone; Liv | 1964 |
SALINE-SOLUBLE PREPARATIONS OF DEOXYRIBONUCLEOPROTEINS.
Topics: Acetates; Alanine; Aminobutyrates; Aminocaproates; Aminocaproic Acid; Animals; Cadmium; Caprylates; | 1964 |
THE IN VIVO EFFECTS OF CORTISOL ON PROTEIN METABOLISM IN NORMAL AND MALIGNANT TISSUES.
Topics: Carcinoma, Hepatocellular; Glycine; Hydrocortisone; Liver; Liver Neoplasms; Neoplasm Proteins; Neopl | 1964 |
[ON THE EFFECT OF ANABOLIC STEROIDS ON THE GLYCINE INCORPORATION INTO MALIGNANT TUMORS AND HOST TISSUE].
Topics: Anabolic Agents; Carbon Isotopes; Glycine; Methenolone; Mice; Neoplasms; Research; Sarcoma; Sarcoma, | 1964 |
THE ALTERATIONS OF NORMAL HUMAN EMBRYONIC CELL STRAINS AFTER CONTINUOUS CULTIVATION IN VITRO AND THEIR COMPARISON WITH CELL STRAINS OF TUMOR ORIGIN.
Topics: Amino Acids; Carcinoma, Squamous Cell; Fetus; Fibroblasts; Glycine; Histocytochemistry; In Vitro Tec | 1964 |
[DIAGNOSTIC SIGNIFICANCE OF SERUM PEPTIDASE DETERMINATION IN BLASTOMATOUS DISEASES].
Topics: Blood; Clinical Enzyme Tests; Diagnosis, Differential; Endopeptidases; Glycine; Heart Failure; Human | 1965 |
THE EFFECTS OF 3'-DEOXYADENOSINE ON THE SYNTHESIS OF RIBONUCLEIC ACID.
Topics: Adenine; Adenosine Triphosphate; Antimetabolites; Antineoplastic Agents; Carbon Isotopes; Carcinoma, | 1965 |
PYRIMIDINE METABOLISM IN TISSUE CULTURE CELLS DERIVED FROM RAT HEPATOMAS. I. SUSPENSION CELL CULTURES DERIVED FROM THE NOVIKOFF HEPATOMA.
Topics: Animals; Carcinoma, Hepatocellular; Cell Culture Techniques; Floxuridine; Fluorouracil; Glycine; Liv | 1965 |
ETHIONINE CARCINOGENESIS IN THE RAT.
Topics: Carbon Isotopes; Carcinogenesis; Carcinogens; Carcinoma, Hepatocellular; DNA; DNA, Neoplasm; Ethioni | 1965 |
HAEMATOLOGICAL EFFECTS OF IONIZING RADIATION IN CANCEROUS MICE.
Topics: Animals; Blood Volume; Bone Marrow; Carbon Isotopes; Carcinoma, Ehrlich Tumor; Cobalt Isotopes; Eryt | 1965 |
The incorporation of glycine-2-C14 into acid soluble nucleotide purines.
Topics: Glycine; Liver; Metabolic Networks and Pathways; Neoplasms; Nucleotides; Purines | 1955 |
Incorporation of glycine-2-C14 into ascites tumor-cell purines as a biological test system.
Topics: Ascites; Glycine; Neoplasms; Nucleic Acids; Purines | 1955 |
Protein turnover in a study of host-tumor relationships.
Topics: Glycine; Neoplasms; Proteolysis | 1955 |
The influence of amino acids and antimetabolities on glycine retention by Ehrlich ascites carcinoma cells.
Topics: Amino Acids; Antimetabolites; Ascites; Glycine; Neoplasms | 1959 |
Track autoradiographic study of the 14C-2-glycine incorporation into the Ehrlich ascites carcinoma cells.
Topics: Ascites; Autoradiography; Biochemical Phenomena; Glycine; Neoplasms | 1959 |
Hadacidin, a new growth-inhibitory substance in human tumor systems.
Topics: Antineoplastic Agents; Glycine; Humans; Neoplasms | 1962 |
Incorporation of labeled glycine in the proteins of tissues of normal and tumor-bearing mice.
Topics: Animals; Glycine; Mice; Neoplasms; Proteins | 1951 |
Tracer studies on the metabolism of the Gardner lymphosarcoma. I. The uptake of radioactive glycine into tumor protein.
Topics: Glycine; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Neoplasms; Radioactive Tracers; Sarcoma | 1951 |
Tracer studies on the metabolism of the Gardner lymphosarcoma. III. The rate of radioactive alanine and glycine uptake into the protein of lymphosarcoma cells and normal spleen cells.
Topics: Alanine; Glycine; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms; Radioactive Tracers; Sarcoma; Spleen | 1951 |
The action of glycine on the liver glycogen of fasting mice, normal and adrenalectomized.
Topics: Adrenal Gland Neoplasms; Adrenal Glands; Animals; Fasting; Glycine; Glycine Agents; Liver; Liver Gly | 1951 |
In vivo studies on incorporation of glycine-2-C14 into proteins and nucleic acid purines.
Topics: Glycine; Neoplasms; Nucleic Acids; Proteins; Purines | 1952 |
Novel peptide ligands for integrin alpha 4 beta 1 overexpressed in cancer cells.
Topics: Alanine; Animals; Binding Sites; Cell Adhesion; Cell Line; Cell Line, Tumor; Cell Proliferation; CHO | 2004 |
Cancer incidence among glyphosate-exposed pesticide applicators in the Agricultural Health Study.
Topics: Adult; Aged; Agriculture; Cohort Studies; Female; Glycine; Glyphosate; Herbicides; Humans; Incidence | 2005 |
Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dioxanes; Enzyme Inhibitors; Glycine; Humans; Hypo | 2006 |
99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours.
Topics: Animals; Carcinoma, Medullary; Cysteine; Edetic Acid; Gastrins; Gene Expression Regulation, Neoplast | 2007 |
Conjugation of arginine-glycine-aspartic acid peptides to poly(ethylene oxide)-b-poly(epsilon-caprolactone) micelles for enhanced intracellular drug delivery to metastatic tumor cells.
Topics: Aldehydes; Arginine; Aspartic Acid; Cell Line, Tumor; Drug Delivery Systems; Glycine; Humans; Lacton | 2007 |
Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar.
Topics: Animals; Carcinogenicity Tests; Carcinogens; Dose-Response Relationship, Drug; Female; Glycine; Hypo | 2007 |
Technetium-99m-labeling and synthesis of thymidine analogs: potential candidates for tumor imaging.
Topics: Chelating Agents; Edetic Acid; Glycine; Isotope Labeling; Ligands; Magnetic Resonance Imaging; Model | 2007 |
Distinct effects of the recurrent Mlh1G67R mutation on MMR functions, cancer, and meiosis.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Cell Line; Chromosomes; Cisplatin; DNA Dam | 2008 |
Rational design of highly active and selective ligands for the alpha5beta1 integrin receptor.
Topics: Angiogenesis Inhibitors; Aza Compounds; Binding Sites; Drug Design; Glycine; Integrin alpha5beta1; I | 2008 |
Metabolic functions of myo-inositol. V. Utilization of glycine and serine in nucleotide and nucleic acid biosynthesis by inositol-deficient KB cells.
Topics: Carbon Isotopes; Culture Techniques; Glycine; Humans; Inositol; Mouth Neoplasms; Neoplasms; Nucleic | 1967 |
Metabolic functions of myo-inositol. VI. Impairment of amino acid transport in KB cells caused by inositol deficiency.
Topics: Aminoisobutyric Acids; Carbon Isotopes; Culture Techniques; Glycine; Humans; Inositol; Kinetics; Mou | 1967 |
Whole-body protein turnover in metabolically stressed patients and patients with cancer as measured with [15N] glycine.
Topics: Adolescent; Adult; Aged; Female; Glycine; Humans; Liver; Liver Function Tests; Male; Middle Aged; Ne | 1983 |
Serum amino acids in weight-losing patients with cancer and tuberculosis.
Topics: Adult; Amino Acids; Body Weight; Citrulline; Female; Glycine; Humans; Lung Neoplasms; Male; Middle A | 1983 |
Whole body protein synthesis and turnover in normal man and malnourished patients with and without known cancer.
Topics: Adult; Aged; Body Weight; Fasting; Female; Glycine; Humans; Male; Middle Aged; Neoplasms; Nitrogen I | 1981 |
Fluorescence high-performance liquid chromatographic determination of free and conjugated bile acids in serum and bile using 1-bromoacetylpyrene as a pre-labeling reagent.
Topics: Bile; Bile Acids and Salts; Chromatography, High Pressure Liquid; Fluorescent Dyes; Glycine; Humans; | 1983 |
Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 ant
Topics: Antigens, Neoplasm; Biomarkers, Tumor; Cell Nucleus; Formaldehyde; Glycine; Humans; Immunohistochemi | 1994 |
Screening for germ line p53 mutations in children with malignant tumors and a family history of cancer.
Topics: Adolescent; Adult; Alleles; Arginine; Base Sequence; Child; Child, Preschool; Exons; Family Health; | 1993 |
Hybridization of a 99Tcm-labelled oligodeoxynucleotide to CAPL RNA.
Topics: Base Sequence; Calcium-Binding Proteins; Chelating Agents; Female; Glycine; Humans; Neoplasms; Nucle | 1998 |
The crystal structure of human cytosolic serine hydroxymethyltransferase: a target for cancer chemotherapy.
Topics: Binding Sites; Catalytic Domain; Crystallography, X-Ray; Cytosol; Dimerization; DNA Replication; Dru | 1998 |
Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene.
Topics: Amino Acid Sequence; Arginine; Aspartic Acid; Breast Neoplasms; Female; Glutamic Acid; Glycine; Huma | 2001 |
Isolation and identification of urinary beta-aspartyl dipeptides and their concentrations in human urine.
Topics: Adolescent; Adult; Aged; Aging; Aspartic Acid; Child; Dipeptides; Female; Glutamates; Glycine; Human | 1978 |
Characterization of a Gly19-->Val mutant of ram p25, a low Mr GTP-binding protein: loss of GTP/GDP-binding activity in the mutated ram p25.
Topics: Amino Acid Sequence; Base Sequence; Cloning, Molecular; Escherichia coli; Genes, ras; Glycine; GTP P | 1992 |
Effect of the route of nutrient administration on whole-body protein kinetics in man.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Energy Intake; Fasting; Female; Food, Formulat | 1987 |
Tracer priming in human protein turnover studies with [15N]glycine.
Topics: Ammonia; Glycine; Humans; Infusions, Parenteral; Injections, Intravenous; Kinetics; Mathematics; Met | 1985 |
Urea inhibition of lactate dehydrogenase. A convenient routine procedure.
Topics: Anemia; Buffers; Clinical Enzyme Tests; Glycine; Humans; Ischemia; L-Lactate Dehydrogenase; Liver; L | 1970 |
[Clinical studies on serum leucyl glycyl glycine hydrolyzing enzyme in cancer. I].
Topics: Adult; Aged; Carcinoma, Hepatocellular; Cobalt; Edetic Acid; Electrophoresis; Female; Glycine; Hepat | 1971 |
[Clinical studies on serum leucyl glycyl glycine hydrolyzing enzyme in cancer. II].
Topics: Adult; Aged; Amino Acids; Aminopeptidases; Female; Glycine; Humans; Leucine; Leucyl Aminopeptidase; | 1971 |
The erythrocyte plasma distribution of amino acids in health and disease.
Topics: Acute Disease; Adolescent; Adult; Alanine; Amino Acids; Anemia, Hemolytic; Anemia, Pernicious; Bronc | 1968 |
Uptake of labelled amino acids into human erythrocytes in disease.
Topics: Acute Disease; Alanine; Amino Acids; Anemia; Bronchitis; Bronchopneumonia; Carbon Isotopes; Erythroc | 1968 |
[The aminoacetone in neoplastic tissues].
Topics: Acetates; Coenzyme A; Glycine; Histocytochemistry; Neoplasms | 1966 |